Ophthalmology – Systemic Lupus Erythematosus

What the Disease Represents

Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease characterized by:

• Autoantibody production
• Immune-complex formation
• Complement activation
• Inflammation and vascular injury

The disease typically follows a:

Relapsing-remitting course

and may affect:

• Skin
• Joints
• Kidneys
• Hematologic system
• Nervous system
• Cardiovascular system
• Eyes

Ocular manifestations may sometimes reflect:

Active or severe systemic lupus.

Why SLE Matters to Ophthalmologists

Almost any ocular structure can be affected.

Important manifestations include:

• Keratoconjunctivitis sicca
• Eyelid discoid lupus lesions
• Episcleritis
• Scleritis
• Peripheral ulcerative keratitis
• Uveitis
• Retinal microangiopathy
• Severe vaso-occlusive retinopathy
• Choroidopathy
• Optic neuropathy
• Cranial neuropathies
• Hydroxychloroquine retinal toxicity

Among these, severe retinal vascular disease and optic nerve involvement are particularly important because they can cause:

Permanent visual loss.

Who Is Most Commonly Affected

SLE occurs predominantly in:

Women of reproductive age

with a female predominance of approximately:

9:1

Disease severity and prevalence vary among populations and are influenced by:

• Genetic susceptibility
• Hormonal factors
• Environmental triggers
• Socioeconomic and healthcare factors

How Autoimmunity Develops

SLE results from loss of tolerance to self-antigens.

Important mechanisms include:

• Abnormal clearance of apoptotic material
• B-cell activation
• Autoantibody production
• Immune-complex deposition
• Complement activation
• Type I interferon signaling
• T-cell dysregulation

Vascular injury may result from:

• Immune-complex vasculopathy
• Endothelial dysfunction
• Thrombosis

Genetic Susceptibility

SLE is polygenic rather than caused by a single gene.

Associations involve:

• HLA loci
• Complement pathways
• Interferon signaling
• B-cell regulation

Family members have increased risk, but inheritance is:

Not Mendelian.

Common Systemic Manifestations

Patients may have:

• Malar rash
• Photosensitivity
• Arthritis
• Oral ulcers
• Serositis
• Nephritis
• Cytopenias
• Neurologic disease
• Constitutional symptoms

Fatigue is particularly common.

Modern Classification Framework

Older teaching used the rule:

4 of 11 ACR criteria

This has largely been replaced for classification purposes by the:

2019 EULAR/ACR criteria

These require:

1. Positive ANA at least once as an entry criterion
2. Weighted clinical and immunologic features
3. A cumulative score of ≥10 points

Classification criteria support research and standardized case definition but do not replace:

Clinical diagnosis by the treating physician.

Important Lupus Autoantibodies

Common serologic markers include:

• ANA – highly sensitive but nonspecific
• Anti-dsDNA – relatively specific and often associated with nephritis/activity
• Anti-Sm – highly specific
• Anti-Ro/SSA
• Anti-La/SSB
• Antiphospholipid antibodies

Complement levels such as:

• C3
• C4

may fall during active disease.

Antiphospholipid Antibody Syndrome

SLE may coexist with:

Antiphospholipid syndrome (APS)

Relevant antibodies include:

• Lupus anticoagulant
• Anticardiolipin antibody
• Anti-β2-glycoprotein I antibody

APS increases risk of:

• Arterial thrombosis
• Venous thrombosis
• Retinal artery occlusion
• Retinal vein occlusion
• Cerebral ischemia

This is particularly important in patients with:

Severe vaso-occlusive retinal disease.

Common Eye Symptoms

Patients may report:

• Dryness
• Burning
• Foreign-body sensation
• Redness
• Photophobia
• Ocular pain
• Floaters
• Diplopia
• Blurred vision
• Sudden visual loss

Symptoms depend heavily on the structure involved.

Eyelid Manifestations

Discoid lupus erythematosus may affect the eyelids.

Findings can include:

• Scaly plaques
• Erythema
• Atrophy
• Dyspigmentation
• Madarosis
• Lid-margin distortion

It may resemble:

• Chronic blepharitis
• Seborrheic disease

Ocular Surface Disease

The most frequent ophthalmic problem is:

Dry eye disease

often related to:

• Lacrimal gland dysfunction
• Secondary Sjögren disease
• Meibomian gland dysfunction
• Medication effects

Corneal Findings

Dry eye may produce:

• Reduced tear meniscus
• Punctate epithelial keratitis
• Filamentary keratitis
• Fluctuating vision

Less commonly SLE may cause:

• Interstitial keratitis
• Peripheral ulcerative keratitis
• Corneal thinning

Peripheral Ulcerative Keratitis

PUK is an uncommon but potentially serious manifestation.

It may occur with:

• Scleritis
• Active systemic vasculitis

Findings include:

• Peripheral epithelial defect
• Stromal thinning
• Inflammatory infiltrate

This should prompt:

Urgent systemic evaluation and immunosuppressive treatment.

Episcleritis

Episcleritis generally causes:

• Sectoral superficial redness
• Mild discomfort
• Normal vision

Superficial episcleral vessels typically:

Blanch with phenylephrine.

It is usually less threatening than scleritis.

Scleritis

Scleritis may present with:

• Deep boring pain
• Violaceous redness
• Globe tenderness
• Possible visual decline

Deep vessels generally:

Do not blanch substantially with phenylephrine.

Scleritis in an SLE patient can indicate:

Significant systemic inflammatory activity.

Anterior Uveitis

Anterior uveitis is less common than ocular surface or retinal disease.

Possible findings include:

• Cells
• Flare
• Posterior synechiae

Severe hypopyon uveitis is unusual and should prompt consideration of:

• Infection
• Behçet disease
• Other inflammatory disorders

Lupus Retinopathy

The classic retinal manifestation is:

Lupus retinal microangiopathy

which reflects systemic vascular injury.

Common findings include:

• Cotton-wool spots
• Intraretinal hemorrhages
• Microaneurysms
• Hard exudates
• Vascular tortuosity

Cotton-wool spots represent:

Focal retinal nerve fiber layer ischemia.

Why Lupus Retinopathy Matters

Retinopathy often correlates with:

• Active systemic disease
• Renal disease
• CNS involvement
• Hypertension

Therefore retinal findings may serve as a marker of:

More severe systemic lupus activity.

Severe Vaso-Occlusive Retinopathy

A much more serious phenotype is:

Occlusive lupus retinal vasculopathy

which can produce:

• Extensive capillary nonperfusion
• Branch retinal artery occlusion
• Central retinal artery occlusion
• Branch retinal vein occlusion
• Central retinal vein occlusion
• Combined arterial and venous occlusion

Role of Antiphospholipid Antibodies

Severe thrombotic retinal vascular disease should raise suspicion for:

Antiphospholipid syndrome

especially when occlusion is:

• Extensive
• Bilateral
• Recurrent
• Occurring at a young age

Ischemic Retinal Complications

Extensive nonperfusion can lead to:

• Retinal neovascularization
• Neovascularization of the disc
• Vitreous hemorrhage
• Fibrovascular proliferation
• Tractional retinal detachment
• Neovascular glaucoma

These complications may threaten vision even after systemic inflammation is controlled.

Fluorescein Angiography

FA is particularly useful when retinal vascular disease is suspected.

It can demonstrate:

• Capillary nonperfusion
• Vascular leakage
• Retinal vasculitis
• Macular ischemia
• Neovascularization

Wide-field angiography can help quantify:

Peripheral retinal ischemia.

OCT

Macular OCT is useful for detecting:

• Macular edema
• Intraretinal fluid
• Subretinal fluid
• Ischemic retinal thinning
• Hydroxychloroquine toxicity

OCT is also important for following:

Structural response to treatment.

OCT Angiography

OCTA may demonstrate:

• Reduced capillary density
• Deep and superficial plexus abnormalities
• Foveal avascular zone enlargement

It can complement FA but cannot directly demonstrate:

Vascular leakage.

Lupus Choroidopathy

SLE may rarely produce:

Choroidal vascular dysfunction

with:

• Serous retinal detachment
• RPE detachments
• Choroidal ischemia
• RPE changes

It is often associated with:

• Severe systemic hypertension
• Lupus nephritis
• Active systemic disease

Why Choroidopathy Can Develop

Possible mechanisms include:

• Choroidal vasculitis
• Immune-complex deposition
• Choroidal ischemia
• Severe hypertension
• RPE dysfunction

These impair normal removal of:

Subretinal fluid.

Distinguishing Lupus Choroidopathy From CSC

This distinction can be challenging because SLE patients may receive corticosteroids, which can precipitate:

Central serous chorioretinopathy

Thus subretinal fluid in an SLE patient may reflect:

• Active lupus choroidopathy
• Steroid-associated CSC
• Hypertensive choroidopathy

The management differs substantially.

Optic Nerve Disease

Optic nerve involvement is uncommon but potentially severe.

Manifestations include:

• Optic neuritis
• Ischemic optic neuropathy
• Optic disc edema
• Optic nerve vasculitis
• Papilledema from raised intracranial pressure

Lupus Optic Neuropathy

Patients may develop:

• Sudden or subacute visual loss
• Dyschromatopsia
• RAPD
• Visual-field defects

Mechanisms may include:

• Inflammation
• Small-vessel ischemia
• Thrombosis

Severe optic neuropathy generally requires:

Urgent systemic treatment.

Neuro-Ophthalmic Manifestations

CNS lupus or associated vascular disease may cause:

• Cranial nerve palsies
• Internuclear ophthalmoplegia
• Homonymous visual-field defects
• Cortical visual loss
• Nystagmus
• Ocular motor abnormalities

When Neuroimaging Is Needed

MRI brain/orbits ± vascular imaging should be considered with:

• Optic neuropathy
• Cranial neuropathy
• Homonymous field loss
• Focal neurologic symptoms
• Suspected CNS vasculitis or thrombosis

Infection Must Always Be Considered

SLE patients are often receiving:

• Corticosteroids
• Antimetabolites
• Biologic agents
• Other immunosuppressive drugs

New ocular inflammation may therefore actually represent:

Infection rather than autoimmune flare.

Important infections include:

• HSV
• VZV
• CMV
• Toxoplasmosis
• Tuberculosis
• Syphilis

Escalating immunosuppression without considering infection can be dangerous.

Dry Eye Treatment

Ocular surface disease may be treated with:

• Preservative-free artificial tears
• Lubricating gel or ointment
• Treatment of meibomian gland dysfunction
• Topical cyclosporine
• Lifitegrast or another approved anti-inflammatory dry-eye therapy

Severe disease may require:

• Serum tears
• Punctal occlusion
• Scleral lenses

Treating Episcleritis

Mild disease may respond to:

• Lubrication
• Oral NSAIDs when necessary

Frequent recurrence should prompt assessment of:

Systemic disease activity.

Treating Scleritis and PUK

These usually require:

Systemic anti-inflammatory/immunosuppressive therapy

rather than topical drops alone.

Treatment may include:

• Systemic corticosteroids
• Steroid-sparing immunomodulators
• Biologic therapy according to systemic disease

Treating Lupus Retinal Vasculitis

Sight-threatening retinal inflammation generally requires:

Rapid systemic control of lupus activity

often using:

• High-dose systemic corticosteroids
• Additional immunosuppression

depending on severity.

Agents may include:

• Mycophenolate
• Cyclophosphamide
• Azathioprine
• Rituximab
• Other disease-directed therapies

Management should be coordinated with:

Rheumatology.

Managing Vaso-Occlusive Disease

If APS or another thrombotic mechanism is present, treatment may require:

Antithrombotic therapy

under systemic specialist supervision.

This may include:

• Anticoagulation
• Selected antiplatelet therapy

Anticoagulation should not be prescribed solely because an SLE patient has retinopathy; it is used when there is an established:

Thrombotic/APS indication.

Managing Retinal Ischemia

Extensive retinal nonperfusion with neovascularization may require:

Panretinal photocoagulation

Anti-VEGF therapy can be useful as an adjunct for:

• Neovascularization
• Macular edema

but it does not replace treatment of the underlying systemic disease.

Vitrectomy

Pars plana vitrectomy may be required for:

• Nonclearing vitreous hemorrhage
• Tractional retinal detachment
• Complex proliferative disease

Treating Lupus Choroidopathy

Treatment centers on correcting the underlying systemic problem:

• Control severe hypertension
• Treat active lupus nephritis
• Suppress systemic inflammation when appropriate

Serous detachments often improve as systemic disease comes under control.

Hydroxychloroquine in SLE

Hydroxychloroquine (HCQ) is a cornerstone systemic therapy for many patients with SLE because it reduces:

• Disease flares
• Thrombotic risk in selected populations
• Long-term organ damage

unless contraindicated.

Its major ophthalmic concern is:

Retinal toxicity.

Hydroxychloroquine Toxicity

HCQ toxicity primarily affects:

• Photoreceptors
• RPE

Typical advanced disease produces:

Bull’s-eye maculopathy

but modern screening aims to detect toxicity well before this appears clinically.

Safe Hydroxychloroquine Dosing

A major modern correction is that dosing should generally be kept at:

≤5 mg/kg/day using actual body weight

rather than the older threshold of 6.5 mg/kg based on ideal body weight.

Major Risk Factors for HCQ Retinopathy

Risk increases with:

• Higher daily dose
• Longer treatment duration
• Renal impairment
• Concurrent tamoxifen use

Pre-existing macular disease may complicate screening interpretation.

Modern HCQ Screening

Patients should have a:

Baseline ophthalmic examination

soon after starting therapy to document pre-existing macular disease and establish an imaging reference.

For patients at standard risk, annual screening generally begins after:

5 years of treatment.

Earlier annual screening is appropriate when major risk factors are present.

Core Hydroxychloroquine Screening Tests

Modern screening relies primarily on:

• Spectral-domain OCT
• Automated visual field testing

Common field strategy:

• 10-2 in many non-Asian patients

Because toxicity may be more pericentral in many Asian patients:

• Wider fields such as 24-2C, 24-2, or 30-2
• Wider OCT assessment

may be appropriate.

Additional HCQ Tests

Useful confirmatory tests include:

• Fundus autofluorescence
• Multifocal ERG

Amsler grid and color vision testing are:

Not sufficiently sensitive as primary screening tests.

Why Early HCQ Detection Is Critical

Hydroxychloroquine toxicity can continue to progress after the drug is stopped because of persistent retinal drug effects.

Therefore:

Established toxicity is irreversible.

The goal of screening is detection before meaningful central visual loss occurs.

Corneal Verticillata From Antimalarials

Antimalarial therapy may also cause:

Corneal verticillata

These whorl-like epithelial deposits are usually:

• Asymptomatic
• Reversible
• Not predictive of retinal toxicity

They generally do not require treatment.

Corticosteroid-Related Eye Problems

Patients treated chronically with systemic or topical steroids are at increased risk of:

• Posterior subcapsular cataract
• Ocular hypertension
• Steroid-induced glaucoma

These complications should be monitored during prolonged therapy.

Multidisciplinary Management

Serious ocular lupus manifestations often require collaboration among:

• Ophthalmology
• Rheumatology
• Nephrology
• Neurology
• Hematology

depending on the systemic phenotype.

Follow-Up Approach

Follow-up is individualized according to:

• Ocular manifestation
• Systemic activity
• Treatment
• Medication toxicity

Monitor as appropriate:

• Visual acuity
• IOP
• Ocular surface
• Optic nerve
• OCT
• Visual fields
• Retinal vascular status

Expected Visual Outcome

Most patients with uncomplicated dry eye or episcleritis maintain:

Excellent visual prognosis.

Visual prognosis becomes more guarded with:

• Severe vaso-occlusive retinopathy
• Macular ischemia
• Optic neuropathy
• Extensive choroidopathy
• Delayed treatment

Features Linked to Poorer Vision

Particularly concerning findings include:

• Extensive retinal capillary nonperfusion
• Macular ischemia
• Central retinal artery occlusion
• Neovascularization
• Optic nerve ischemia
• Recurrent severe inflammatory disease

Long-Term Eye Complications

Potential complications include:

• Chronic dry eye
• Corneal ulceration
• Scleritis
• Cataract
• Glaucoma
• Retinal vascular occlusion
• Vitreous hemorrhage
• Tractional retinal detachment
• Neovascular glaucoma
• Macular ischemia
• Optic neuropathy
• Permanent visual loss

High-Yield Takeaways

• SLE is a multisystem autoimmune disease capable of affecting essentially every ocular structure.
• The most common ophthalmic manifestation is usually ocular surface disease/dry eye, often associated with Sjögren disease.
• Lupus retinopathy classically produces cotton-wool spots, hemorrhages, microaneurysms, and vascular abnormalities.
• Retinal vascular disease may parallel active systemic or CNS lupus and can therefore be an important marker of disease severity.
• Severe vaso-occlusive retinopathy can produce extensive capillary nonperfusion, artery or vein occlusion, retinal neovascularization, vitreous hemorrhage, and tractional retinal detachment.
• Severe retinal thrombosis should raise suspicion for antiphospholipid syndrome.
• Anticoagulation is used for an appropriate APS/thrombotic indication, not automatically for all lupus retinopathy.
• Lupus choroidopathy may produce serous retinal detachment and is often associated with severe hypertension or lupus nephritis.
• In an SLE patient on corticosteroids, subretinal fluid may alternatively represent steroid-associated central serous chorioretinopathy.
• Scleritis and peripheral ulcerative keratitis generally require systemic treatment and may indicate severe autoimmune activity.
• Optic neuropathy is uncommon but potentially devastating and requires urgent systemic evaluation.
• In immunosuppressed SLE patients, always consider infection before labeling new ocular inflammation as a lupus flare.
• Hydroxychloroquine is an important systemic therapy for SLE, but retinal screening is essential.
• Modern HCQ dosing should generally be ≤5 mg/kg/day based on actual body weight.
• The major HCQ toxicity risk factors are high dose, long treatment duration, renal impairment, and tamoxifen use.
• Modern HCQ screening emphasizes OCT plus automated visual fields, with wider pericentral testing particularly important in many Asian patients.
• The old reliance on Amsler grid, color testing, or visible bull’s-eye maculopathy represents late and inadequate screening.
• Vision-threatening retinal vasculitis or choroidopathy requires rapid systemic disease control with rheumatology collaboration.
• The prognosis is generally good for mild ocular disease but can be poor with macular ischemia, severe vaso-occlusion, or optic nerve involvement.

Ophthalmology – Sympathetic Ophthalmia

What the Disease Represents

Sympathetic ophthalmia (SO) is a rare, bilateral, diffuse granulomatous panuveitis that develops after:

• Penetrating ocular trauma
• Intraocular surgery
• Occasionally other procedures that disrupt the uveal tissues

The injured or operated eye is traditionally called the:

Exciting/inciting eye

and the fellow eye is called the:

Sympathizing eye

Although only one eye is initially injured, the subsequent autoimmune inflammation typically affects:

Both eyes.

⸻

Why the Fellow Eye Becomes Inflamed

The leading mechanism is an autoimmune response to previously sequestered ocular antigens released after disruption of the:

• Uvea
• Retina
• Choroid

This produces:

T-cell-mediated immune attack against melanocyte- and retinal-associated antigens

in both eyes.

⸻

How Rare It Is

Sympathetic ophthalmia is:

Very uncommon

even after severe penetrating trauma or intraocular surgery.

The risk is higher after:

• Open-globe injury
• Repeated intraocular surgery
• Extensive uveal manipulation

but remains low overall.

⸻

When It Can Appear

SO can begin:

• Within days
• Within weeks
• Within months
• Years or even decades after the inciting injury

Most cases occur relatively early after trauma, but:

A very remote history of ocular injury does not exclude the diagnosis.

⸻

Important Clinical Trigger

Always ask about:

• Previous open-globe trauma
• Ocular surgery
• Multiple retinal procedures
• Previous removal or repair of a severely injured eye

A history of ocular penetration in a patient with bilateral granulomatous panuveitis should immediately raise suspicion for:

Sympathetic ophthalmia.

⸻

What the Patient Usually Notices

Symptoms may include:

• Blurred vision
• Photophobia
• Ocular pain
• Redness
• Floaters
• Metamorphopsia

The fellow eye may initially develop subtle symptoms before severe inflammation becomes apparent.

⸻

What the Anterior Segment Can Show

Typical findings include:

• Granulomatous keratic precipitates
• Anterior chamber cells and flare
• Posterior synechiae
• Iris thickening
• Ciliary injection

The degree of anterior inflammation varies.

⸻

Vitreous Involvement

Vitreous inflammation may include:

• Cells
• Haze

This contributes to the classification as:

Panuveitis

rather than isolated choroiditis.

⸻

Characteristic Posterior Segment Findings

Posterior manifestations may include:

• Multifocal serous retinal detachments
• Diffuse choroidal thickening
• Optic disc edema
• Choroidal infiltrates
• Dalen–Fuchs nodules
• Retinal edema

These findings can closely resemble:

Vogt–Koyanagi–Harada disease.

⸻

Dalen–Fuchs Nodules

Dalen–Fuchs nodules are small yellow-white lesions located at the level of:

• RPE
• Bruch membrane

They correspond histologically to collections of epithelioid cells beneath the RPE.

They are characteristic but:

Not pathognomonic

and may also be seen in VKH.

⸻

Serous Retinal Detachment

One of the most important vision-threatening findings is:

Exudative retinal detachment

caused by severe choroidal inflammation and breakdown of the outer blood-retinal barrier.

OCT is particularly useful for documenting:

• Subretinal fluid
• RPE undulations
• Choroidal thickening

⸻

Histopathologic Pattern

Classic pathology shows:

• Diffuse granulomatous choroiditis
• Lymphocytes, predominantly T cells
• Epithelioid histiocytes
• Multinucleated giant cells

The choriocapillaris is often relatively spared early.

Dalen–Fuchs nodules may be present between:

• RPE
• Bruch membrane

⸻

How the Diagnosis Is Made

There is:

No single confirmatory blood test

Diagnosis is based on:

1. Compatible bilateral granulomatous uveitis
2. History of prior penetrating ocular trauma or surgery
3. Characteristic multimodal imaging
4. Exclusion of important mimics

⸻

Optical Coherence Tomography

OCT may demonstrate:

• Multifocal subretinal fluid
• RPE folds
• Septa within serous detachments
• Outer retinal disruption
• Choroidal thickening on enhanced-depth imaging

Serial OCT is valuable for monitoring treatment response.

⸻

Fluorescein Angiography

FA classically shows:

• Multiple pinpoint areas of early hyperfluorescence
• Progressive leakage
• Pooling beneath areas of serous retinal detachment
• Optic disc leakage

This pattern strongly resembles VKH.

⸻

Indocyanine Green Angiography

ICGA may show:

• Multiple hypofluorescent dark dots
• Delayed choroidal perfusion
• Diffuse choroidal inflammatory abnormalities

ICGA can reveal disease activity not obvious clinically.

⸻

Fundus Autofluorescence

FAF may demonstrate:

• Hyperautofluorescent areas of active RPE stress
• Hypoautofluorescent areas of established RPE atrophy

It is useful for documenting:

Chronic RPE damage.

⸻

B-Scan Ultrasonography

B-scan may demonstrate:

• Choroidal thickening
• Serous retinal detachment

It is particularly useful when:

• Media opacity limits fundus visualization

⸻

Important Diagnostic Mimics

The major differential diagnoses include:

• Vogt–Koyanagi–Harada disease
• Sarcoidosis
• Tuberculosis
• Syphilis
• Posterior scleritis
• Primary vitreoretinal lymphoma
• Other granulomatous panuveitides

⸻

Distinguishing SO From VKH

Sympathetic Ophthalmia

• Prior ocular trauma or surgery
• Bilateral granulomatous panuveitis
• Dalen–Fuchs nodules
• Serous retinal detachments

Vogt–Koyanagi–Harada Disease

• No preceding penetrating ocular injury
• May have neurologic/auditory symptoms
• May develop:
• Vitiligo
• Poliosis
• Alopecia

The ocular appearance can be nearly identical.

⸻

Infectious Disease Must Be Excluded

Before major immunosuppression, evaluate for important mimics such as:

• Tuberculosis
• Syphilis

and other infections when clinically indicated.

This is especially important before:

• Biologic therapy
• Long-term systemic immunosuppression

⸻

HLA Associations

Various HLA associations have been reported, including:

• HLA-DR4-related alleles

However:

HLA testing has no routine diagnostic role.

⸻

Immediate Treatment Goal

The central objective is:

Rapid and sustained suppression of intraocular inflammation before irreversible retinal, choroidal, and optic nerve damage develops.

Treatment should generally be:

Aggressive from the outset.

⸻

First-Line Systemic Treatment

Acute disease is usually treated with:

High-dose systemic corticosteroids

such as oral prednisone, often around:

1 mg/kg/day

depending on severity.

Severe disease may require:

IV methylprednisolone pulse therapy

for rapid control.

⸻

Why a Slow Steroid Taper Matters

Inflammation may recur when corticosteroids are tapered too quickly.

Therefore tapering is usually:

Slow and guided by clinical and imaging evidence of quiescence.

OCT and angiography can detect persistent posterior inflammation even when symptoms improve.

⸻

Early Steroid-Sparing Therapy

Modern management often favors:

Early introduction of immunomodulatory therapy

rather than relying on prolonged high-dose corticosteroids alone.

This reduces:

• Steroid toxicity
• Recurrence
• Chronic inflammation

⸻

Common Immunomodulatory Agents

Options include:

• Mycophenolate mofetil
• Methotrexate
• Azathioprine
• Cyclosporine
• Tacrolimus

Choice depends on:

• Disease severity
• Comorbidities
• Patient age
• Specialist experience

⸻

Biologic Therapy

Refractory or severe disease may respond to:

• Adalimumab
• Infliximab

Other biologic agents may be used in selected cases.

These generally require:

• TB screening
• Hepatitis screening
• Multidisciplinary monitoring

⸻

Local Steroid Therapy

Periocular or intravitreal corticosteroid can be useful as an adjunct for:

• Persistent macular edema
• Asymmetric inflammation

However:

Local treatment alone is usually inadequate for a bilateral systemic autoimmune process such as SO.

⸻

Role of Steroid Implants

Long-acting intravitreal corticosteroid implants may control inflammation in selected cases but carry risks including:

• Cataract
• Ocular hypertension
• Glaucoma

They are not a universal substitute for systemic immunomodulation.

⸻

The Old “14-Day Enucleation Rule”

Traditional teaching stated that a blind traumatized eye should be enucleated within:

14 days

to prevent sympathetic ophthalmia.

This rule is now considered:

Oversimplified and not strongly evidence-based.

Because SO is rare and visual potential may be difficult to judge immediately after trauma, prophylactic removal should not be automatic.

⸻

When Enucleation May Still Be Considered

Early enucleation may be considered when an injured eye is:

• Irreversibly blind
• Severely disorganized
• Painful
• Without realistic visual potential

The decision should balance:

• Possibility of visual recovery
• Structural integrity
• Pain
• Risk of infection
• Patient preference

⸻

What to Do Once Sympathetic Ophthalmia Has Started

After SO has developed:

Removal of the exciting eye generally does not reliably improve inflammation or visual outcome in the sympathizing eye.

Therefore an eye with useful or potentially useful vision should not be removed simply because SO has begun.

⸻

Enucleation vs Evisceration

Historically, enucleation was favored over evisceration because retained uveal tissue was thought to increase SO risk.

Modern data suggest the absolute risk after either procedure is:

Extremely low

but enucleation remains the traditional choice when removal of a severely traumatized eye is undertaken specifically in the context of concern about sympathetic ophthalmia.

⸻

Management of Cataract

Chronic inflammation and steroid therapy can cause:

Cataract

Surgery should ideally be performed when inflammation has been:

Well controlled for a sustained period

with appropriate perioperative anti-inflammatory coverage.

⸻

Management of Glaucoma

Glaucoma may result from:

• Chronic uveitis
• Peripheral anterior synechiae
• Corticosteroid therapy

Treatment may require:

• Topical medications
• Laser in selected situations
• Glaucoma surgery

while maintaining adequate inflammatory control.

⸻

Macular Complications

Visual loss may result from:

• Persistent serous retinal detachment
• Cystoid macular edema
• RPE atrophy
• Subretinal fibrosis
• Photoreceptor loss

OCT is central to monitoring these complications.

⸻

Follow-Up During Active Disease

Patients require:

Close and frequent review

with assessment of:

• Visual acuity
• Anterior chamber activity
• Vitreous inflammation
• IOP
• Optic nerve
• OCT
• Choroidal/retinal activity

Severe disease may initially require review:

• Every few days
• Weekly

depending on response.

⸻

Long-Term Monitoring

Even after apparent remission, recurrence can occur.

Long-term follow-up should monitor for:

• Recurrent uveitis
• Cataract
• Glaucoma
• Macular edema
• RPE/choroidal atrophy
• Immunosuppressive drug toxicity

⸻

Expected Visual Outcome

Modern aggressive immunosuppression has greatly improved prognosis.

Many patients can retain:

Useful central vision

if inflammation is treated early and sustained remission is achieved.

Poorer outcomes are associated with:

• Delayed diagnosis
• Recurrent inflammation
• Chronic serous detachment
• Glaucoma
• Macular scarring
• Optic nerve damage

⸻

Major Ocular Complications

Potential complications include:

• Bilateral visual loss
• Cataract
• Secondary glaucoma
• Cystoid macular edema
• Serous retinal detachment
• Subretinal fibrosis
• RPE atrophy
• Chorioretinal scarring
• Optic nerve damage

⸻

High-Yield Takeaways

• Sympathetic ophthalmia is a rare bilateral granulomatous panuveitis occurring after penetrating ocular trauma or intraocular surgery.
• The injured eye is the exciting/inciting eye, and the fellow eye is the sympathizing eye.
• The disease is thought to result from T-cell-mediated autoimmunity against previously sequestered ocular antigens.
• SO can occur days to decades after ocular injury, so even remote trauma is relevant.
• Classic posterior findings include multifocal serous retinal detachments, diffuse choroidal thickening, optic disc edema, and Dalen–Fuchs nodules.
• Dalen–Fuchs nodules are characteristic but not pathognomonic and may also occur in VKH.
• FA typically shows multiple pinpoint leaks with late pooling beneath serous detachments.
• OCT is essential for monitoring subretinal fluid, outer retinal injury, and choroidal thickening.
• The main clinical mimic is Vogt–Koyanagi–Harada disease; the key discriminator is a history of ocular trauma or surgery.
• Tuberculosis, syphilis, sarcoidosis, and other granulomatous disorders should be excluded when appropriate.
• Treatment requires prompt high-dose systemic corticosteroids.
• Because recurrence is common and long-term steroid toxicity is substantial, modern care often uses early steroid-sparing immunomodulatory therapy.
• Mycophenolate, methotrexate, azathioprine, cyclosporine, tacrolimus, and biologics such as adalimumab or infliximab may be used depending on severity.
• The traditional rule that a blind traumatized eye must be enucleated within 14 days is not supported as an absolute modern standard.
• Once SO has developed, removing the exciting eye does not reliably improve the fellow eye and should not be done solely for that purpose when the eye has useful visual potential.
• Long-term prognosis is substantially better with early aggressive control of inflammation and sustained immunomodulation.

Ophthalmology – Superior Limbic Keratoconjunctivitis

What the Disorder Represents

Superior limbic keratoconjunctivitis (SLK) is a chronic, recurrent ocular-surface disorder involving the:

• Superior bulbar conjunctiva
• Superior limbus
• Superior corneal epithelium
• Superior tarsal conjunctiva

It is usually:

• Bilateral
• Often asymmetric
• More common in middle-aged women

Typical symptoms include:

• Foreign-body sensation
• Burning
• Photophobia
• Ocular discomfort
• Fluctuating vision

Symptoms may appear disproportionately severe relative to the initial examination.

The Classic Clinical Pattern

The characteristic constellation includes:

• Superior bulbar conjunctival injection
• Redundant or lax superior bulbar conjunctiva
• Marked superior conjunctival staining
• Fine papillary reaction of the superior tarsal conjunctiva
• Superior punctate epithelial keratopathy
• Mucus strands or corneal filaments

This superior distribution is one of the most useful diagnostic clues.

Who Is Most Often Affected

SLK most commonly occurs in:

• Middle-aged adults
• Women more often than men

It can occur at other ages, especially when associated with:

• Thyroid eye disease
• Severe dry eye disease
• Contact lens-related mechanical irritation

Strongest Systemic Association

The classic association is:

Thyroid disease, particularly Graves disease/thyroid eye disease

A substantial proportion of patients with SLK have:

• Current thyroid disease
• Previous thyroid disease
• Clinical signs of thyroid eye disease

Therefore thyroid history should always be reviewed.

Why Thyroid Eye Disease Promotes SLK

Thyroid eye disease can produce:

• Upper-lid retraction
• Tight upper eyelid
• Proptosis
• Increased blink friction
• Exposure
• Tear-film instability

These factors increase mechanical interaction between the:

Upper lid and superior bulbar conjunctiva

and may contribute to development of SLK.

Other Important Associations

SLK is also associated with:

• Aqueous-deficient dry eye
• Meibomian gland dysfunction
• Filamentary keratitis
• Superior conjunctivochalasis
• Chronic contact lens wear

Older reports also described associations with:

• Thimerosal-containing contact lens solutions

which are now much less relevant because thimerosal is rarely used in modern contact lens care.

How the Disease Probably Develops

The exact mechanism is not fully established.

The leading model is:

Mechanical microtrauma + tear-film deficiency + chronic ocular-surface inflammation

Repeated friction occurs between:

• Tight superior eyelid
• Redundant superior bulbar conjunctiva
• Superior limbus

This produces:

• Epithelial injury
• Abnormal conjunctival keratinization
• Inflammation
• Mucus production

Role of Conjunctivochalasis

Some patients have excessive mobility or redundancy of the superior bulbar conjunctiva.

The loose conjunctiva is repeatedly dragged across the:

Superior cornea and limbus during blinking

which may perpetuate inflammation.

This mechanical component explains why procedures that:

• Resect
• Tighten
• Cauterize

the superior conjunctiva can improve refractory disease.

Typical Symptoms

Patients commonly describe:

• Grittiness
• Foreign-body sensation
• Burning
• Photophobia
• Tearing
• Ocular pain or discomfort
• Intermittent blurred vision

Symptoms usually fluctuate with:

• Dry environments
• Prolonged visual activity
• Exacerbation of dry eye

Why Pain May Seem Disproportionate

Surface disease may be localized to a relatively small superior area but remain highly symptomatic because:

• The superior lid repeatedly rubs the inflamed tissue
• Corneal epithelial defects are painful
• Filaments can mechanically pull on corneal epithelium

Therefore symptom severity may exceed the apparent extent of disease.

Superior Bulbar Conjunctival Findings

The hallmark finding is:

Localized superior bulbar conjunctival inflammation

typically from approximately:

• 10 to 2 o’clock

Findings may include:

• Hyperemia
• Thickening
• Redundancy
• Loss of normal smooth surface
• Lissamine green staining

Superior Tarsal Conjunctival Findings

Upper-lid eversion may reveal:

Fine, velvety papillary hypertrophy

of the superior palpebral conjunctiva.

This is generally finer than the giant papillae seen with:

• Giant papillary conjunctivitis
• Vernal keratoconjunctivitis

Corneal Findings

Corneal involvement typically affects the:

Superior cornea

and may include:

• Punctate epithelial erosions
• Superior epithelial keratitis
• Mucus adherence
• Filamentary keratitis

Severe disease can produce significant discomfort and fluctuating vision.

Filamentary Keratitis

Filaments consist of:

• Mucus
• Degenerated epithelial cells

adhering to compromised corneal epithelium.

They may cause:

• Sharp pain
• Foreign-body sensation
• Photophobia

Mechanical removal can provide temporary relief but does not address the underlying SLK.

Tear-Film Abnormalities

Patients frequently demonstrate:

• Reduced tear meniscus
• Short tear break-up time
• Increased mucus
• Reduced Schirmer values

This reflects frequent coexistence of:

Dry eye disease.

Testing the Mobility of the Superior Conjunctiva

After topical anesthesia, the examiner may gently manipulate the superior bulbar conjunctiva.

In SLK, it may be unusually:

• Mobile
• Redundant

and may be displaced toward the superior cornea more easily than normal.

This supports a mechanical component but is not required for diagnosis.

Ocular Surface Staining

Lissamine green is especially useful for highlighting abnormal superior conjunctival epithelium.

It may show intense staining of the:

• Superior bulbar conjunctiva
• Superior limbal region

Fluorescein is useful for detecting:

• Corneal epithelial disease

Rose bengal can also stain damaged epithelium but is used less often because it causes more discomfort.

Why Lissamine Green Is Preferred

Lissamine green:

• Highlights devitalized or mucin-deficient epithelium
• Is usually better tolerated
• Is particularly useful for documenting the superior conjunctival component

The distribution of staining can be more diagnostically useful than total staining severity.

Schirmer Testing

Schirmer testing may be useful when aqueous-deficient dry eye is suspected.

A reduced result supports coexisting:

Keratoconjunctivitis sicca

but does not itself diagnose SLK.

Thyroid Evaluation

Patients without a known thyroid disorder should be assessed for symptoms or signs such as:

• Weight change
• Heat intolerance
• Palpitations
• Tremor
• Lid retraction
• Proptosis

Laboratory evaluation may include:

• TSH
• Free T4

with further thyroid testing guided by clinical findings.

Routine parathyroid testing is not standard in modern evaluation unless there is another clinical indication.

What Pathology Shows

Histopathology may demonstrate:

• Squamous metaplasia
• Keratinization of conjunctival epithelium
• Inflammatory cell infiltration
• Goblet-cell abnormalities

These changes support chronic epithelial trauma and inflammation.

Biopsy is:

Not usually necessary for diagnosis.

Conditions That Can Mimic SLK

Important differentials include:

• Dry eye disease
• Filamentary keratitis
• Allergic conjunctivitis
• Giant papillary conjunctivitis
• Vernal keratoconjunctivitis
• Atopic keratoconjunctivitis
• Contact lens-related disease
• Conjunctivochalasis
• Toxic medicamentosa
• Mucus fishing syndrome

Distinguishing It From Giant Papillary Conjunctivitis

SLK

• Superior bulbar conjunctival staining
• Superior limbal involvement
• Fine papillary tarsal reaction
• Often associated with dry eye or thyroid disease

GPC

• Large papillae on upper tarsal conjunctiva
• Often associated with contact lenses or exposed sutures
• Mucous discharge and lens intolerance are prominent

Distinguishing It From Vernal Keratoconjunctivitis

Vernal disease more commonly features:

• Younger patients
• Severe itching
• Giant cobblestone papillae
• Limbal Horner-Trantas dots
• Seasonal exacerbation

SLK more often affects:

Middle-aged adults with superior bulbar conjunctival disease and mechanical friction.

First Treatment Priority

Management should begin by treating contributing ocular-surface disease.

Common first steps include:

• Preservative-free artificial tears
• Lubricating gel or ointment
• Management of meibomian gland dysfunction
• Reduction of toxic topical medications
• Modification or discontinuation of contact lens wear when contributory

Treating Coexisting Dry Eye

Dry eye management may include:

• Frequent preservative-free tears
• Nighttime ointment
• Warm compresses
• Lid hygiene
• Environmental modification
• Moisture-chamber glasses

Improving the tear film can substantially reduce:

Friction and epithelial injury.

Anti-Inflammatory Eye Drops

A short course of:

Topical corticosteroid

may be useful for significant inflammatory flares.

Because repeated steroid treatment can cause:

• Ocular hypertension
• Glaucoma
• Cataract

IOP should be monitored when treatment is prolonged or recurrent.

Steroid-Sparing Surface Therapy

Longer-term inflammatory control may include:

• Topical cyclosporine
• Lifitegrast in selected patients
• Other dry-eye anti-inflammatory agents

These are particularly useful when significant dry eye coexists.

Filament Management

Filamentary keratitis may be treated with:

• Intensive lubrication
• Mechanical filament removal
• Topical N-acetylcysteine in selected cases
• Bandage contact lens when appropriate

Recurrence is common unless the underlying ocular-surface disease is controlled.

Role of Autologous Serum Tears

For severe refractory surface disease, autologous serum tears can provide:

• Epitheliotrophic growth factors
• Improved lubrication
• Better epithelial healing

They may be particularly useful when significant dry eye coexists with SLK.

Punctal Occlusion

Punctal plugs or cautery may help patients with substantial:

Aqueous tear deficiency

but significant surface inflammation should generally be controlled first.

Therapeutic Contact Lenses

A:

• Bandage soft contact lens
• Scleral lens

may reduce friction and improve symptoms in selected cases.

However, contact lens-associated mechanical irritation can also worsen SLK in some patients, so treatment must be individualized.

Silver Nitrate – Historical Perspective

Older treatment protocols frequently used:

0.5–1% silver nitrate

applied to the superior conjunctiva.

This can chemically cauterize abnormal epithelium and occasionally relieve symptoms.

However, silver nitrate is now used much less frequently because of the risk of:

• Chemical injury
• Corneal toxicity
• Scleral injury

and because safer medical and surgical options are available.

Important Silver Nitrate Safety Point

If silver nitrate is used by an experienced clinician:

Solid silver nitrate sticks should never be applied directly to the ocular surface.

They can produce severe chemical burns.

When Surgery Is Considered

Surgery is appropriate when:

• Symptoms remain severe
• Medical therapy fails
• Redundant superior conjunctiva is prominent
• Mechanical friction is clearly contributing

Superior Conjunctival Resection

One of the most effective surgical approaches is:

Resection of redundant superior bulbar conjunctiva

often with removal of adjacent:

Tenon tissue

The goal is to reduce:

• Conjunctival redundancy
• Superior friction
• Recurrent epithelial trauma

Conjunctival Resection With Tenonectomy

Removing both redundant conjunctiva and abnormal underlying Tenon tissue may reduce recurrence.

Treatment typically involves the superior region spanning roughly:

10 to 2 o’clock

although the extent is individualized.

Conjunctival Cauterization

Thermocautery or other controlled conjunctival cautery can:

• Tighten redundant tissue
• Reduce mobility
• Decrease mechanical trauma

It can be effective in appropriately selected patients.

Why Mechanical Procedures Work

Surgical and cautery procedures do not primarily suppress inflammation.

Instead they address the mechanical cycle:

Redundant conjunctiva → lid friction → epithelial injury → inflammation

by physically reducing conjunctival redundancy.

Supratarsal Steroid Injection

Supratarsal corticosteroid injection has been reported to improve refractory SLK.

However, it is not a routine first-line treatment because it can cause:

• IOP elevation
• Steroid response
• Other injection-related complications

It should be reserved for selected cases under specialist supervision.

Relationship to Thyroid Treatment

Treating systemic thyroid dysfunction is important for overall health.

However:

Correction of thyroid hormone levels alone does not necessarily eliminate SLK

because associated mechanical abnormalities such as:

• Lid retraction
• Proptosis
• Tight upper eyelid

may persist.

When Eyelid Surgery May Matter

In patients with significant thyroid eye disease and upper-lid retraction, correction of eyelid position may reduce:

• Exposure
• Mechanical friction

and can sometimes improve recurrent ocular-surface disease.

Follow-Up Approach

Follow-up depends on severity.

Monitor:

• Symptoms
• Superior conjunctival staining
• Corneal staining
• Filaments
• Tear-film status
• IOP if corticosteroids are used

Stable mild disease may be reviewed periodically, while severe epithelial disease requires closer observation.

Expected Clinical Course

SLK is usually:

Chronic and relapsing

Patients may experience:

• Exacerbations
• Partial remissions
• Long symptom-free intervals

Some cases improve spontaneously over time.

Visual Prognosis

The visual prognosis is generally:

Excellent

because SLK usually does not cause permanent intraocular damage.

Vision may fluctuate due to:

• Tear-film instability
• Corneal epithelial disease

Severe permanent visual loss is uncommon.

Problems That Can Develop

Potential complications include:

• Filamentary keratitis
• Persistent corneal epithelial defects
• Severe dry-eye symptoms
• Contact lens intolerance
• Steroid-induced ocular hypertension from treatment
• Rare chronic corneal surface damage

High-Yield Takeaways

• Superior limbic keratoconjunctivitis is a chronic inflammatory and mechanical disorder of the superior ocular surface.
• The classic pattern is superior bulbar conjunctival injection/staining + redundant superior conjunctiva + fine superior tarsal papillae + superior punctate keratitis or filaments.
• SLK is usually bilateral but asymmetric and occurs most often in middle-aged women.
• The strongest systemic association is thyroid disease, particularly thyroid eye disease.
• Mechanical friction between a tight upper lid and redundant superior bulbar conjunctiva is thought to be central to pathogenesis.
• Coexisting aqueous-deficient dry eye and meibomian gland dysfunction are common and should be actively treated.
• Lissamine green staining of the superior bulbar conjunctiva is particularly useful diagnostically.
• Fine superior tarsal papillae differ from the giant papillae of GPC or vernal keratoconjunctivitis.
• Initial treatment emphasizes preservative-free lubrication and management of associated dry eye.
• Short courses of topical corticosteroid can control inflammatory flares, while cyclosporine or other steroid-sparing dry-eye agents may be useful for chronic disease.
• Filamentary keratitis may require filament removal, intensive lubrication, and N-acetylcysteine in selected cases.
• Silver nitrate is a historical treatment and is used much less often today because of the risk of chemical ocular injury.
• Refractory disease with prominent conjunctival redundancy may respond well to superior conjunctival resection with or without Tenonectomy or controlled cauterization.
• Supratarsal steroid injection is an option in selected cases but requires awareness of steroid-induced IOP elevation.
• The disorder often follows a relapsing-remitting course, but long-term visual prognosis is generally excellent.

Ophthalmology – Subconjunctival Hemorrhage

What the Finding Represents

A subconjunctival hemorrhage (SCH) is extravasation of blood from small conjunctival vessels into the potential space beneath the conjunctiva.

It typically appears as a:

• Sharply demarcated bright-red patch
• Flat or mildly elevated area of blood over the sclera
• Painless red eye with otherwise preserved vision

The blood is trapped beneath the transparent conjunctiva and therefore appears striking despite usually being:

Benign and self-limited.

Why the Eye Looks So Red

Small conjunctival vessels rupture and blood accumulates between the:

• Conjunctiva
• Episcleral surface

Unlike conjunctivitis, there is usually:

• No significant discharge
• No diffuse conjunctival inflammation
• No corneal involvement

Common Clinical Patterns

SCH may be:

• Spontaneous
• Valsalva-related
• Traumatic
• Postoperative
• Recurrent

Most isolated spontaneous cases have no serious underlying disorder.

Common Triggers

Frequent precipitating events include:

• Coughing
• Sneezing
• Vomiting
• Constipation/straining
• Heavy lifting
• Vigorous exercise
• Eye rubbing
• Minor unnoticed trauma

These transiently increase venous pressure and can rupture fragile conjunctival vessels.

Systemic Factors That Increase Risk

Associated conditions include:

• Hypertension
• Diabetes mellitus
• Platelet disorders
• Coagulopathy

Medication-associated risk is increased with:

• Anticoagulants
• Antiplatelet agents

Examples include:

• Warfarin
• Direct oral anticoagulants
• Aspirin
• Clopidogrel

Other Ocular Associations

SCH may occur after:

• Contact lens trauma
• Intravitreal injection
• Cataract or glaucoma surgery
• Conjunctival surgery
• Local anesthetic injection
• Viral conjunctivitis

It can also accompany more substantial ocular trauma.

Typical Symptoms

Most patients simply notice:

A painless red patch on the eye

often discovered:

• In a mirror
• By a family member
• Incidentally

Vision should remain:

Normal.

Minor Associated Sensations

Some patients report:

• Mild foreign-body sensation
• Slight fullness
• Mild irritation

Significant:

• Pain
• Photophobia
• Visual loss

is not typical and should prompt consideration of another or additional diagnosis.

Typical Examination Appearance

The hemorrhage is usually:

• Bright red initially
• Well circumscribed
• Located beneath the conjunctiva
• Nonblanching

The underlying sclera may be completely obscured within the involved area.

How the Appearance Changes During Healing

As the hemorrhage resolves, the color may evolve from:

• Bright red
• Dark red
• Brown
• Yellow

similar to a resolving bruise.

This does not indicate infection.

How Long It Takes to Resolve

Most uncomplicated SCH clears spontaneously within approximately:

1–2 weeks

Larger hemorrhages may require:

2–3 weeks or occasionally longer.

Blood may appear to spread during the first few days because of redistribution beneath the conjunctiva, even though the total hemorrhage is not necessarily increasing.

What Should Be Checked in a Routine Case

For an isolated atraumatic SCH, assess:

• Visual acuity
• External eye
• Cornea
• Anterior chamber

It is also reasonable to check:

Blood pressure

particularly in older adults or patients with recurrent hemorrhage.

When the History Matters More

Ask about:

• Trauma
• Recent surgery
• Coughing or vomiting
• Heavy straining
• Anticoagulant use
• Antiplatelet therapy
• Easy bruising
• Epistaxis
• Gum bleeding
• Previous similar episodes

Recurrent unexplained episodes warrant more investigation than a single typical event.

When Trauma Changes the Situation

A traumatic SCH should not automatically be assumed benign.

A complete ocular examination is necessary to exclude:

• Open-globe injury
• Hyphema
• Corneal or scleral laceration
• Intraocular foreign body
• Orbital injury

A Major Trauma Red Flag

After significant trauma, a:

Bullous, extensive, or 360-degree subconjunctival hemorrhage

can be associated with occult:

Globe rupture.

Particular concern exists when accompanied by:

• Poor vision
• Irregular pupil
• Shallow or abnormally deep anterior chamber
• Low IOP
• Uveal prolapse
• Severe pain

Such cases require urgent ophthalmic assessment.

When Imaging Is Appropriate

Imaging is not needed for routine spontaneous SCH.

In significant ocular/orbital trauma, imaging may include:

CT of the orbits

when evaluating for:

• Fracture
• Intraocular foreign body
• Orbital injury

If open globe is suspected, avoid unnecessary pressure on the eye.

When Laboratory Testing Is Unnecessary

Routine blood testing is generally:

Not required for a single uncomplicated SCH

in an otherwise healthy patient.

When Blood Tests Become Appropriate

Consider investigation when hemorrhages are:

• Recurrent
• Bilateral and unexplained
• Unusually extensive
• Associated with easy bruising or systemic bleeding

Possible tests include:

• CBC with platelet count
• PT/INR
• aPTT

Additional studies should be guided by the clinical history.

Patients Taking Warfarin

For a patient on warfarin with recurrent or unexpectedly large SCH, check:

INR

to ensure anticoagulation is within the intended therapeutic range.

Do Not Stop Anticoagulation Automatically

An isolated SCH is usually not an indication to stop:

• Anticoagulants
• Antiplatelet medications

Discontinuing these agents can expose patients to serious:

• Thromboembolic
• Cardiovascular
• Cerebrovascular

risk.

Any medication adjustment should be coordinated with the prescribing clinician.

Conditions That Can Look Similar

Important alternatives include:

• Conjunctivitis
• Episcleritis
• Scleritis
• Conjunctival vascular lesion
• Traumatic conjunctival laceration

The absence of pain, discharge, photophobia, and visual loss generally favors SCH.

Distinguishing It From Episcleritis

Subconjunctival Hemorrhage

• Sharply demarcated blood
• No visible branching vascular pattern
• Painless
• Nonblanching

Episcleritis

• Dilated superficial vessels
• Mild tenderness possible
• Vessels remain individually visible
• Often partially blanch with phenylephrine

Distinguishing It From Scleritis

Scleritis generally produces:

• Severe deep pain
• Violaceous rather than bright-red color
• Globe tenderness
• Deep vascular congestion

These features are not typical of an uncomplicated SCH.

Treatment in the Usual Case

No specific therapy is required.

Management consists primarily of:

Reassurance and observation.

The blood is gradually resorbed spontaneously.

Relieving Mild Irritation

If mild foreign-body sensation occurs, use:

• Artificial tears
• Lubricating drops

These improve comfort but do not make the hemorrhage disappear faster.

Large or Elevated Hemorrhages

A large elevated or bullous SCH near the limbus can rarely disturb the adjacent tear film and produce:

Corneal dellen

from localized dehydration.

Management may include:

• Frequent lubrication
• Lubricating ointment

and closer ophthalmic observation.

What Not to Do

Routine treatment does not require:

• Antibiotics
• Topical corticosteroids
• Vasoconstrictor drops

These do not accelerate blood resorption.

Follow-Up Needs

An isolated uncomplicated SCH usually requires:

No scheduled ophthalmic follow-up

provided that:

• Vision remains normal
• There is no significant trauma
• Symptoms resolve as expected

When Reassessment Is Appropriate

Review is appropriate if:

• Hemorrhage repeatedly recurs
• It persists unusually long
• It continues enlarging substantially
• Pain develops
• Vision decreases
• Significant ocular trauma occurred

Recurrent Subconjunctival Hemorrhage

Repeated episodes should prompt reassessment for:

• Hypertension
• Anticoagulation
• Platelet disorders
• Coagulopathy
• Recurrent mechanical trauma

Rarely, persistent localized recurrent hemorrhage can be associated with:

• Conjunctival vascular lesions
• Amyloid deposition
• Other local conjunctival pathology

SCH in Newborns

Subconjunctival hemorrhage may occur in newborns after:

• Vaginal delivery
• Instrument-assisted delivery

It usually resolves spontaneously and is generally benign when isolated.

Expected Outcome

The prognosis for uncomplicated SCH is:

Excellent.

It does not usually cause:

• Permanent visual loss
• Corneal damage
• Intraocular bleeding

The main issue is its alarming appearance.

Potential Complications

Complications are rare.

Possible problems include:

• Corneal dellen adjacent to a very elevated hemorrhage
• Identification of previously unrecognized systemic bleeding disorder
• Associated ocular injury when SCH results from significant trauma

The hemorrhage itself usually leaves:

No permanent ocular damage.

High-Yield Takeaways

• Subconjunctival hemorrhage is blood trapped beneath the conjunctiva and usually presents as a painless, sharply demarcated bright-red patch with normal vision.
• Common precipitants include coughing, sneezing, vomiting, straining, eye rubbing, and minor trauma.
• Important systemic associations include hypertension, anticoagulant or antiplatelet therapy, thrombocytopenia, and coagulation disorders.
• Most isolated spontaneous cases are benign and require reassurance only.
• Resolution typically occurs within 1–2 weeks, although large hemorrhages may persist longer.
• Mild spreading or color change during healing is usually normal.
• Routine laboratory testing is not indicated for a single uncomplicated episode.
• Recurrent or unexplained SCH should prompt consideration of blood pressure measurement, CBC/platelets, PT/INR, and aPTT according to the clinical setting.
• Do not automatically discontinue anticoagulants or antiplatelet medications because of an isolated SCH.
• Significant pain, photophobia, or reduced vision is not characteristic and should prompt evaluation for another diagnosis.
• Following trauma, an extensive, bullous, or 360-degree SCH may be a warning sign of occult globe rupture.
• A large elevated hemorrhage near the limbus can rarely cause corneal dellen, for which lubrication and follow-up are appropriate.
• The long-term prognosis is excellent, and uncomplicated SCH does not normally damage vision.

Ophthalmology – Sturge–Weber Syndrome

What the Syndrome Represents

Sturge–Weber syndrome (SWS) is a sporadic congenital neurocutaneous vascular disorder characterized by variable involvement of:

• Facial port-wine birthmark/capillary malformation
• Leptomeningeal vascular malformation
• Ocular vascular abnormalities

The classic ophthalmic manifestations are:

• Glaucoma
• Diffuse choroidal hemangioma
• Episcleral/conjunctival vascular dilation

Not every patient has all three systems involved.

The Modern Genetic Basis

SWS is usually caused by a postzygotic somatic activating mutation in:

GNAQ

most commonly involving:

p.Arg183Gln (R183Q)

Because the mutation occurs after fertilization:

• Only a subset of cells carries it
• Disease distribution is mosaic
• Severity varies substantially
• SWS is usually not inherited

This explains why familial transmission is exceedingly uncommon.

Relationship to Port-Wine Birthmarks

The facial lesion traditionally called a nevus flammeus is more accurately termed a:

Port-wine birthmark or capillary malformation

It is caused by ectatic dermal capillaries and is present from birth.

Color may range from:

• Pale pink
• Red
• Dark red
• Purple

Over time, untreated lesions may become:

• Darker
• Thicker
• Nodular

Distribution of the Facial Birthmark

Older descriptions classified lesions according to:

• V1
• V2
• V3 trigeminal dermatomes

Modern understanding is that facial capillary malformations follow:

Embryologic vascular territories rather than true trigeminal nerve dermatomes.

The distribution most strongly associated with intracranial SWS is:

Forehead and upper-eyelid involvement

particularly when the lesion crosses the midline forehead or involves a broad frontotemporal region.

Why Upper-Eyelid Involvement Matters

A port-wine birthmark involving the:

Upper eyelid

substantially raises concern for:

• Ipsilateral glaucoma
• Ocular vascular abnormalities
• Possible intracranial involvement

These children warrant early ophthalmic assessment.

How Common It Is

SWS is rare, with an estimated frequency of roughly:

1 in 20,000–50,000 live births

depending on the population studied.

There is no strong:

• Sex predilection
• Racial predilection

The Main Eye Problems

Ocular manifestations can include:

• Glaucoma
• Diffuse choroidal hemangioma
• Dilated conjunctival vessels
• Dilated episcleral vessels
• Retinal vascular tortuosity
• Serous retinal detachment
• Refractive error
• Anisometropia
• Amblyopia
• Buphthalmos in early-onset glaucoma

Glaucoma in SWS

Glaucoma is one of the most important causes of visual morbidity.

It is usually:

• Ipsilateral to the facial capillary malformation
• More likely when the eyelids are involved

Glaucoma may present:

• In infancy
• During childhood
• In adolescence
• In adulthood

Therefore risk is:

Lifelong.

Why Glaucoma Develops

Two major mechanisms are recognized.

Early-Onset Glaucoma

Usually related to:

Developmental angle abnormalities

similar to congenital glaucoma.

Later-Onset Glaucoma

More often related to:

Elevated episcleral venous pressure

caused by abnormal episcleral and orbital venous drainage.

Many patients have a combination of both mechanisms.

Early-Onset Glaucoma Features

Infants may develop:

• Buphthalmos
• Enlarged corneal diameter
• Corneal edema
• Haab striae
• Photophobia
• Tearing

Because the infant eye is elastic, elevated IOP can enlarge the globe.

Later-Onset Glaucoma Features

Older children and adults may show:

• Elevated IOP
• Open angles
• Dilated episcleral vessels
• Progressive optic nerve cupping
• Visual-field loss

The eye may not be enlarged.

Episcleral Vascular Abnormalities

Dilated episcleral vessels are common and may appear:

• Tortuous
• Engorged
• Reddish-purple

These vessels reflect abnormal venous drainage and can contribute directly to:

Elevated IOP.

Why Glaucoma Surgery Is More Difficult

Eyes with SWS are at increased risk during glaucoma surgery because of:

• Elevated episcleral venous pressure
• Choroidal vascular congestion
• Diffuse choroidal hemangioma

Complications may include:

• Choroidal effusion
• Serous retinal detachment
• Suprachoroidal hemorrhage
• Hypotony-related complications

Careful surgical planning is therefore essential.

Diffuse Choroidal Hemangioma

A characteristic ocular finding is a:

Diffuse choroidal hemangioma

usually involving the eye ipsilateral to the facial birthmark.

Unlike a circumscribed choroidal hemangioma, the lesion:

• Has poorly defined borders
• Involves a broad area of choroid
• Produces generalized choroidal thickening

The Classic “Tomato-Ketchup” Fundus

Because of diffuse choroidal vascular thickening, the affected fundus may appear:

Deep red-orange

compared with the fellow eye.

This is classically described as the:

“Tomato-ketchup fundus.”

How a Diffuse Choroidal Hemangioma Affects Vision

The lesion itself may initially be asymptomatic.

Visual loss develops when it causes:

• Subretinal fluid
• Serous retinal detachment
• Macular edema
• RPE alterations
• Refractive changes

Chronic fluid can produce permanent photoreceptor damage.

Other Posterior Segment Findings

Additional findings can include:

• Retinal vascular tortuosity
• Dilated retinal vessels
• RPE mottling
• Serous retinal detachment
• Chronic macular structural damage

Ultrasound Findings

B-scan ultrasonography may demonstrate:

• Diffuse choroidal thickening

A-scan typically shows:

High internal reflectivity

consistent with a vascular lesion.

Ultrasound can be particularly useful when:

• Fundus visualization is difficult
• Tumor thickness needs documentation

OCT in Choroidal Disease

Enhanced-depth imaging OCT may demonstrate:

• Increased choroidal thickness
• Expanded choroidal vascular spaces
• Subretinal fluid
• RPE abnormalities

Macular OCT is particularly useful for monitoring:

Exudation and treatment response.

Fluorescein and Indocyanine Green Angiography

Angiography may help define vascular abnormalities.

ICGA can show:

• Diffuse choroidal hypervascularity
• Abnormal choroidal filling
• Late washout patterns

It is mainly used when treatment planning or diagnostic uncertainty exists.

Neurologic Involvement

The characteristic CNS lesion is:

Leptomeningeal capillary-venous malformation

usually affecting the cerebral hemisphere ipsilateral to the facial lesion.

Commonly involved regions include:

• Occipital lobe
• Parietal lobe
• Posterior frontal regions

Why the Brain Becomes Injured

Abnormal leptomeningeal venous drainage can produce:

• Chronic venous congestion
• Reduced cerebral perfusion
• Ischemic injury
• Cortical atrophy
• Calcification

Over time this can lead to:

• Seizures
• Stroke-like episodes
• Hemiparesis
• Visual-field defects
• Developmental impairment

Seizures

Seizures are the most common neurologic manifestation.

They often begin in:

• Infancy
• Early childhood

Early-onset and poorly controlled seizures are associated with greater risk of:

• Developmental delay
• Neurologic disability

Stroke-Like Episodes

Patients may develop transient or persistent:

• Hemiparesis
• Hemiplegia
• Language disturbance
• Visual-field loss

These episodes are thought to relate to:

• Venous congestion
• Perfusion abnormalities
• Seizure-related metabolic stress

rather than conventional embolic stroke in many cases.

Visual-Field Loss From Brain Disease

Occipital cortical involvement can produce:

Contralateral homonymous hemianopia

or other retrochiasmal visual-field defects.

Thus visual impairment in SWS may originate from:

• Eye disease
• Brain disease
• Both

Headache and Migraine

Headache is common and may resemble:

• Migraine with aura
• Migraine without aura

Headache can coexist with:

• Seizures
• Transient neurologic deficits

Developmental and Cognitive Effects

Neurologic disease may be associated with:

• Developmental delay
• Learning difficulties
• Intellectual disability
• Behavioral problems

Severity correlates broadly with:

• Extent of brain involvement
• Seizure burden
• Age at seizure onset

Best Neuroimaging Test

The preferred study is:

Contrast-enhanced MRI of the brain

often supplemented with:

• Susceptibility-weighted imaging
• Perfusion imaging
• Other advanced sequences

MRI can demonstrate:

• Leptomeningeal enhancement
• Cortical atrophy
• Enlarged deep medullary veins
• Abnormal venous drainage
• Calcification-related signal changes

Role of CT

CT may demonstrate classic:

Gyriform cortical calcification

historically called:

“Tram-track” calcification

However, CT is no longer the preferred screening modality in children because of:

• Ionizing radiation
• Lower sensitivity for early leptomeningeal disease

Important Limitation of Early MRI

A normal MRI in a young infant does:

Not always completely exclude early SWS brain involvement.

If clinical suspicion remains high or neurologic symptoms develop, repeat imaging may be necessary.

Who Needs Neurologic Evaluation

Particular concern exists in children with:

• Forehead port-wine birthmark
• Upper-eyelid involvement
• Seizures
• Developmental abnormalities
• Focal neurologic deficits

Evaluation should be coordinated with:

Pediatric neurology.

An Important Modern Correction About Choroidal Hemangioma

Older teaching suggested that choroidal hemangioma almost always implies:

Leptomeningeal angiomatosis

This is too strong.

Diffuse choroidal hemangioma should raise suspicion for SWS, but intracranial involvement must be established by:

• Clinical evaluation
• Appropriate neuroimaging

rather than assumed.

How the Diagnosis Is Established

Diagnosis is clinical and based on some combination of:

• Facial capillary malformation
• Ocular abnormalities
• Leptomeningeal vascular malformation

Not every patient has the complete classic triad.

Patients With Only a Facial Port-Wine Birthmark

A facial port-wine birthmark alone does:

Not automatically mean Sturge–Weber syndrome.

Risk depends strongly on:

• Location
• Extent
• Associated ocular findings
• Neurologic findings

Important Differential Diagnoses

Consider:

• Klippel–Trénaunay syndrome
• Phakomatosis pigmentovascularis
• Isolated facial capillary malformation
• Other cerebral vascular malformations
• Diffuse choroidal hemangioma without classic SWS

Klippel–Trénaunay Syndrome

This condition typically features:

• Capillary malformation of an extremity
• Venous/lymphatic malformations
• Limb hypertrophy or overgrowth

It should not simply be considered “SWS plus an extremity port-wine stain”; it is a distinct vascular-overgrowth disorder.

Treating the Port-Wine Birthmark

The principal treatment is:

Pulsed-dye laser therapy

Treatment often begins in:

• Infancy
• Early childhood

Earlier treatment may improve:

• Lightening
• Cosmetic outcome
• Prevention of later thickening

Multiple sessions are usually required.

Treating Glaucoma Medically

Topical IOP-lowering therapy may include:

• Beta-blockers
• Carbonic anhydrase inhibitors
• Prostaglandin analogues
• Alpha-2 agonists when age-appropriate

There is no universal rigid first-, second-, and third-line order.

Treatment should be individualized according to:

• Age
• IOP
• Optic nerve status
• Systemic contraindications

Why Medical Therapy Often Becomes Insufficient

SWS glaucoma can be difficult to control because elevated episcleral venous pressure limits aqueous drainage.

Many patients eventually require:

Surgery.

Angle Surgery in Young Children

For early-onset glaucoma with developmental angle abnormality, options include:

• Goniotomy
• Trabeculotomy

These are most useful when angle dysgenesis is a major component.

Filtering Surgery

Older children and adults may require:

• Trabeculectomy
• Glaucoma drainage device

However, elevated episcleral venous pressure can reduce success and increase postoperative complications.

Glaucoma Drainage Devices

Tube shunts may be useful for:

• Refractory glaucoma
• Failed previous procedures
• High-risk filtering surgery

Examples include:

• Ahmed valve
• Baerveldt implant

Cyclodestructive Procedures

Cyclophotocoagulation may be considered in:

• Refractory glaucoma
• Limited visual potential
• Multiple prior surgical failures

It is generally not the first surgical choice in an eye with good visual potential.

Treating Diffuse Choroidal Hemangioma

Treatment is indicated when the hemangioma causes:

• Subretinal fluid
• Macular involvement
• Serous retinal detachment
• Significant visual loss

Observation is reasonable when the lesion is:

• Asymptomatic
• Nonexudative

Photodynamic Therapy

Verteporfin photodynamic therapy (PDT) is an important treatment for symptomatic choroidal hemangioma.

Advantages include:

• Selective vascular closure
• Resolution of subretinal fluid
• Relative preservation of surrounding retina

It is particularly useful when the exudative area is sufficiently localized for treatment.

Radiotherapy

Extensive diffuse choroidal hemangioma may require:

• Low-dose external beam radiotherapy
• Proton beam therapy
• Plaque radiotherapy in selected cases

Radiation is especially useful for:

• Broad diffuse lesions
• Extensive serous detachment
• Disease unsuitable for focal PDT

Why Conventional Laser Is Less Attractive

Thermal laser photocoagulation has historically been used, but it may produce:

• RPE damage
• Chorioretinal scarring

Modern management more commonly favors:

• PDT
• Radiotherapy

depending on lesion extent.

Correcting Refractive Error

SWS may produce:

• Myopia
• Hyperopia
• Astigmatism
• Anisometropia

Early optical correction is important, particularly in children.

Preventing Amblyopia

Amblyopia may result from:

• Anisometropia
• Glaucoma
• Corneal enlargement
• Retinal disease
• Strabismus

Treatment may include:

• Spectacle correction
• Contact lenses
• Patching
• Atropine penalization in selected cases

Early intervention is important for visual development.

Treating Seizures

Neurologic therapy commonly includes:

Antiseizure medication

with the objective of rapid and sustained seizure control.

Refractory epilepsy may require evaluation at a:

Pediatric epilepsy center.

Neurosurgical Options

For severe medically refractory epilepsy arising predominantly from one damaged hemisphere, surgery may include:

• Focal cortical resection
• Hemispherotomy
• Functional hemispherectomy

Modern epilepsy surgery generally favors disconnection procedures rather than older anatomical hemispherectomy techniques.

Role of Low-Dose Aspirin

Low-dose aspirin has been used in selected children with SWS in an attempt to reduce:

• Stroke-like episodes
• Seizure-associated ischemic events

However:

It is not a universal treatment for every SWS patient.

Use should be individualized by neurology after weighing:

• Potential benefit
• Bleeding risk
• Age
• Clinical phenotype

Multidisciplinary Follow-Up

Depending on disease involvement, care may include:

• Ophthalmology
• Neurology
• Dermatology
• Epileptology/neurosurgery
• Developmental pediatrics
• Physical and occupational therapy

Ophthalmic Surveillance

Children at ocular risk require regular assessment of:

• IOP
• Corneal diameter
• Axial length in selected cases
• Optic nerve
• Refraction
• Amblyopia
• Choroid
• Retina

Follow-up frequency depends on:

• Age
• Glaucoma status
• Ocular findings

Why Lifelong Eye Follow-Up Is Needed

Glaucoma may first appear:

Years after infancy

even when neonatal examinations were normal.

Therefore patients with high-risk facial or ocular involvement require:

Long-term surveillance.

Expected Visual Outcome

Visual prognosis depends primarily on:

• Glaucoma control
• Amblyopia prevention
• Macular involvement from choroidal hemangioma
• Serous retinal detachment
• Neurologic visual-field defects

Good vision can be maintained when ocular disease is identified and managed early.

Factors Affecting Neurologic Outcome

Poorer neurologic prognosis is associated with:

• Early seizure onset
• Frequent uncontrolled seizures
• Extensive bilateral or hemispheric brain involvement
• Recurrent stroke-like episodes

Some patients with limited disease have:

Normal intelligence and near-normal life expectancy.

Major Long-Term Complications

Important complications include:

• Glaucoma
• Buphthalmos
• Optic nerve damage
• Amblyopia
• Serous retinal detachment
• Macular photoreceptor damage
• Homonymous visual-field loss
• Seizures
• Hemiparesis
• Developmental impairment

High-Yield Takeaways

• Sturge–Weber syndrome is a sporadic neurocutaneous vascular disorder usually caused by a somatic mosaic GNAQ mutation.
• The classic manifestations involve facial capillary malformation, leptomeningeal vascular malformation, and ocular vascular disease, but not every patient has the full triad.
• The facial lesion is better termed a port-wine birthmark/capillary malformation, not simply a nevus distributed along trigeminal dermatomes.
• Forehead and upper-eyelid involvement carries particularly important risk for ocular and neurologic disease.
• The major ophthalmic threats are glaucoma and diffuse choroidal hemangioma.
• SWS glaucoma may be caused by developmental angle abnormalities in early childhood and elevated episcleral venous pressure later in life.
• Glaucoma risk is lifelong, so a normal infant examination does not eliminate the need for later surveillance.
• Early-onset glaucoma can produce buphthalmos, corneal enlargement, and Haab striae.
• The classic diffuse choroidal hemangioma produces the “tomato-ketchup fundus.”
• Choroidal hemangioma becomes clinically important when it causes subretinal fluid, macular edema, or serous retinal detachment.
• PDT is useful for selected symptomatic choroidal hemangiomas; extensive diffuse disease may require low-dose radiotherapy or proton therapy.
• Contrast-enhanced MRI is preferred for evaluating leptomeningeal involvement; CT mainly demonstrates later cortical calcification.
• Early MRI can occasionally be falsely reassuring, so repeat imaging may be needed when neurologic suspicion remains high.
• Choroidal hemangioma does not automatically prove leptomeningeal involvement.
• Seizures are the most frequent neurologic manifestation and require early aggressive management.
• Low-dose aspirin is used in selected neurologic cases but is not routine therapy for every patient.
• Glaucoma surgery may be technically difficult because of elevated episcleral venous pressure and the risk of choroidal effusion or hemorrhage.
• Early refraction and amblyopia therapy are essential in children.
• Long-term care requires coordinated ophthalmic, neurologic, dermatologic, and developmental follow-up.

Ophthalmology – Stickler Syndrome

What the Syndrome Represents

Stickler syndrome is an inherited collagen disorder characterized by a variable combination of:

• Abnormal vitreous architecture
• High myopia
• Peripheral retinal degeneration
• Markedly increased risk of rhegmatogenous retinal detachment
• Hearing impairment
• Craniofacial abnormalities
• Early-onset arthropathy

From an ophthalmic standpoint, the most important complication is:

Retinal detachment, often occurring at a young age and sometimes bilaterally.

Why the Retina and Vitreous Are Affected

Stickler syndrome results from pathogenic variants affecting structural collagens important in:

• Vitreous
• Cartilage
• Inner ear
• Craniofacial development

Relevant collagens include:

• Type II
• Type IX
• Type XI

Abnormal collagen alters vitreous development and increases:

Vitreoretinal traction and peripheral retinal susceptibility to breaks.

How Common It Is

Stickler syndrome is among the more common inherited connective-tissue disorders.

Estimated prevalence is approximately:

1 in 7,500–10,000

although milder cases may go unrecognized.

Main Genetic Forms

The most important forms are:

Type 1 Stickler Syndrome

Caused by:

COL2A1

Inheritance:

Autosomal dominant

This is the most common form and usually has prominent ocular involvement.

Type 2 Stickler Syndrome

Caused by:

COL11A1

Inheritance:

Autosomal dominant

Often associated with:

• Ocular disease
• Hearing loss
• Craniofacial features

A characteristic vitreous phenotype may be present.

Type 3 Stickler Syndrome

Caused by:

COL11A2

Inheritance is usually:

Autosomal dominant

Because COL11A2 is not expressed in the vitreous, this form is classically:

Nonocular Stickler syndrome

with mainly:

• Hearing
• Skeletal
• Craniofacial manifestations

Recessive Stickler Syndrome

Autosomal recessive forms may result from pathogenic variants in:

• COL9A1
• COL9A2
• COL9A3

These can also produce significant ocular disease.

Other rare Stickler-like collagen disorders continue to be genetically characterized.

Important COL2A1 Nuance

An older teaching stated that COL2A1 mutations must involve exon 2 for ocular disease.

That is:

Incorrect as a general rule.

Many COL2A1 variants outside exon 2 produce classic ocular Stickler syndrome.

However, variants involving the alternatively spliced:

Exon 2

can produce a predominantly or nearly exclusively ocular phenotype because that exon is particularly relevant to vitreous collagen expression.

How It Is Inherited

Most classic Stickler syndrome is:

Autosomal dominant

Therefore an affected individual typically has a:

50% chance of transmitting the pathogenic variant to each child.

However, expression is variable, so family members with the same mutation may differ substantially in:

• Myopia
• Hearing loss
• Joint disease
• Retinal complications

Why Family History May Be Misleading

A negative family history does not exclude Stickler syndrome because:

• Disease expression can be mild
• Relatives may have been undiagnosed
• De novo pathogenic variants can occur
• Ocular and systemic features vary considerably

The Classic Vitreous Phenotypes

Vitreous examination can provide an important diagnostic clue.

COL2A1 / Type 1

Classically associated with:

Membranous vitreous phenotype

with:

• Retrolental membrane-like condensation
• Optically empty vitreous cavity

COL11A1 / Type 2

Classically associated with:

Beaded vitreous phenotype

with:

• Irregular fibrillar condensations
• Bead-like strands

These patterns are helpful but are not absolutely present in every patient.

Optically Empty Vitreous

A striking finding can be:

Abnormally clear or optically empty central vitreous

with abnormal peripheral condensations or veils.

This may initially look deceptively normal unless the examiner specifically searches for the characteristic vitreous architecture.

Myopia

High myopia is very common and may be present:

• Congenitally
• In early childhood

Unlike ordinary school-age myopia, Stickler-associated myopia may be:

High from a very young age

and may not necessarily show the same progressive axial pattern as conventional myopia.

Why Early Refraction Matters

Uncorrected high ametropia can cause:

• Reduced visual development
• Refractive amblyopia
• Strabismus

Therefore children require:

Early cycloplegic refraction and prompt optical correction.

Peripheral Retinal Abnormalities

Peripheral findings may include:

• Lattice degeneration
• Radial or circumferential vitreoretinal degeneration
• Retinal holes
• Horseshoe tears
• Giant retinal tears

The peripheral retina must therefore be examined carefully.

Why Retinal Detachment Risk Is So High

The combination of:

• Abnormal vitreous
• Strong vitreoretinal adhesions
• Peripheral retinal degeneration
• High myopia

creates a strong predisposition to:

Rhegmatogenous retinal detachment.

Detachment can occur:

• In childhood
• In adolescence
• In young adulthood

and may be bilateral.

How High Is the Retinal Detachment Risk?

Lifetime risk is substantial, particularly in:

COL2A1-associated type 1 Stickler syndrome.

Published estimates vary according to genotype and cohort, but untreated high-risk families may have retinal detachment rates:

Well above those of the general population and sometimes exceeding 50%.

Risk should therefore be considered clinically significant even in an asymptomatic child.

Character of Retinal Detachment in Stickler Syndrome

Detachments may be unusually complex because they can involve:

• Multiple retinal breaks
• Giant retinal tears
• Extensive vitreoretinal traction
• Bilateral disease
• Proliferative vitreoretinopathy

This makes repair potentially more difficult than routine RRD.

Why the Fellow Eye Matters

A patient presenting with Stickler-associated RD in one eye remains at substantial risk in the:

Fellow eye

and requires careful peripheral retinal examination and discussion of:

• Surveillance
• Prophylactic options

Cataract Pattern

Stickler syndrome may be associated with cataract, classically:

Peripheral cortical wedge-shaped cataract

Other cataract morphologies can also occur.

Cataract may develop:

• Spontaneously
• Earlier than expected for age

Glaucoma

Glaucoma occurs in a subset of patients.

Potential mechanisms include:

• Developmental angle abnormalities
• Secondary changes
• Postoperative factors

Long-term examination should therefore include:

• IOP
• Optic nerve assessment

Hearing Abnormalities

Hearing loss is common, especially in certain genotypes.

It may be:

• Sensorineural
• Conductive
• Mixed

Severity ranges widely.

Formal:

Audiologic assessment

is recommended when Stickler syndrome is suspected or confirmed.

Craniofacial Findings

Characteristic facial features can include:

• Midface hypoplasia
• Flat nasal bridge
• Anteverted nares
• Micrognathia

Findings may become less obvious with age.

Pierre Robin Sequence

Stickler syndrome is an important genetic cause of:

Pierre Robin sequence

which consists of:

• Micrognathia
• Glossoptosis
• Upper-airway obstruction

often accompanied by:

• Cleft palate

Palatal Abnormalities

Patients may have:

• Cleft palate
• Submucous cleft
• Bifid uvula

A subtle palatal abnormality may provide an important clue in a patient presenting primarily with retinal disease.

Skeletal Manifestations

Musculoskeletal features may include:

• Joint hypermobility in childhood
• Joint pain
• Early degenerative osteoarthritis
• Spondyloepiphyseal abnormalities
• Mild scoliosis

Some patients develop significant arthritis relatively early in adulthood.

Height and Body Habitus

Body habitus is variable.

Patients may have:

• Slender build
• Long extremities

but classic Marfan-type disproportion is not required.

Mitral Valve Prolapse – Modern Perspective

Older descriptions frequently emphasized:

Mitral valve prolapse

as a common Stickler association.

Modern evidence does not support routine cardiologic screening solely for Stickler syndrome in otherwise asymptomatic patients.

Cardiac evaluation should instead be driven by:

• Clinical findings
• Murmur
• Symptoms
• Additional connective-tissue features

How the Diagnosis Is Suspected

History should specifically ask about:

• High myopia from childhood
• Retinal tear or detachment
• Family history of RD
• Cleft palate
• Pierre Robin sequence
• Hearing loss
• Early arthritis

The combination of:

Early high myopia + abnormal vitreous + retinal detachment history

is particularly suggestive.

What the Eye Examination Should Include

A complete evaluation includes:

• Visual acuity
• Cycloplegic refraction in children
• Slit-lamp examination
• Vitreous assessment
• Dilated peripheral retinal examination
• Scleral depression when appropriate
• IOP
• Optic nerve examination

Why Vitreous Examination Is Crucial

Recognizing the characteristic:

• Membranous
• Beaded
• Optically empty

vitreous phenotype can allow diagnosis before:

A retinal detachment occurs.

This may provide the opportunity for:

• Genetic confirmation
• Family screening
• Preventive retinal management

Role of Wide-Field Imaging

Ultra-widefield photography can help:

• Document peripheral lesions
• Follow previously treated retina
• Educate patients and families

However:

Wide-field imaging does not replace a careful dilated peripheral examination, particularly when tractional breaks are suspected.

Genetic Testing

Modern diagnosis increasingly includes:

Molecular genetic testing

using connective-tissue or inherited vitreoretinopathy panels.

Testing may identify variants in:

• COL2A1
• COL11A1
• COL11A2
• COL9A1
• COL9A2
• COL9A3

Why Genetic Confirmation Matters

A molecular diagnosis helps with:

• Confirming the syndrome
• Determining ocular risk
• Identifying relatives at risk
• Reproductive counseling
• Distinguishing ocular from nonocular subtypes

This is particularly important because phenotype can be:

Highly variable.

Screening Family Members

First-degree relatives should be considered for:

• Dilated retinal examination
• Refraction
• Vitreous assessment
• Genetic counseling/testing where appropriate

A mildly affected parent may only be recognized after a child presents with:

• High myopia
• Cleft palate
• Retinal detachment

Conditions That Can Look Similar

Important differentials include:

• Wagner syndrome
• Knobloch syndrome
• Marfan syndrome
• High/pathologic myopia
• Familial exudative vitreoretinopathy
• Ehlers-Danlos syndromes
• Other inherited vitreoretinopathies

Stickler vs Wagner Syndrome

Wagner syndrome may produce:

• Abnormal vitreous
• Peripheral chorioretinal degeneration
• Cataract

but generally lacks the typical systemic:

• Cleft palate
• Hearing
• Arthropathy

features of Stickler syndrome.

Stickler vs Marfan Syndrome

Marfan syndrome more typically features:

• Ectopia lentis
• Tall skeletal habitus
• Aortic root disease

whereas Stickler syndrome more strongly features:

• Abnormal vitreous
• High myopia
• Retinal detachment
• Cleft palate
• Hearing loss

First Ophthalmic Priorities

Management focuses on:

• Correcting refractive error
• Treating amblyopia
• Detecting peripheral retinal pathology
• Preventing or rapidly treating retinal detachment
• Managing cataract and glaucoma when present

There is no medication that corrects the underlying collagen defect.

Refractive Management

Children should receive prompt optical correction with:

• Spectacles
• Contact lenses when appropriate

Amblyopia therapy should be started early when indicated.

Retinal Detachment Education

Patients and families should know the warning symptoms:

• Sudden new floaters
• Flashes of light
• Curtain or shadow
• Sudden peripheral field loss
• Sudden decrease in vision

These require:

Urgent retinal examination.

Prophylactic Retinopexy

One of the most important modern management questions is whether to perform prophylactic treatment before retinal detachment occurs.

In high-risk Stickler syndrome, particularly genetically confirmed:

COL2A1-associated type 1 disease

some specialist centers recommend prophylactic peripheral retinopexy.

Methods include:

• 360-degree cryotherapy
• 360-degree or extensive peripheral laser retinopexy

Evidence for Prophylactic Treatment

Large observational studies, particularly from the Cambridge Stickler service, suggest that prophylactic treatment can:

Substantially reduce the incidence of retinal detachment in type 1 Stickler syndrome.

However:

• Treatment technique varies
• Randomized trial evidence is limited
• Practice differs among vitreoretinal specialists

Therefore prophylaxis should be individualized by a retina specialist experienced with:

Inherited vitreoretinopathies.

When Prophylaxis Is Especially Considered

Factors favoring discussion include:

• Confirmed high-risk genotype
• Strong family history of RD
• Fellow-eye retinal detachment
• Extensive peripheral abnormalities
• Inability to access urgent retinal care

Why Focal Laser Alone May Not Be Enough

Stickler detachments may arise from:

• New retinal tears at different locations
• Giant retinal tears

Therefore simply treating one isolated lattice lesion may not address the broader inherited peripheral retinal risk.

This is why some preventive strategies use:

Extensive circumferential prophylaxis.

Repairing Retinal Detachment

Established RRD requires prompt vitreoretinal surgery.

Depending on anatomy, treatment may include:

• Pars plana vitrectomy
• Scleral buckle
• Combined buckle-vitrectomy
• Gas tamponade
• Silicone oil in complex cases

Why Surgery Can Be Challenging

Stickler eyes may have:

• Giant retinal tears
• Multiple retinal breaks
• Abnormal vitreoretinal adhesion
• Proliferative vitreoretinopathy

Repeat surgery may therefore be required.

Cataract Surgery Considerations

Cataract surgery can restore vision when lens opacity is significant.

However, these patients already have high baseline RD risk.

Before surgery:

• Carefully examine the peripheral retina
• Treat significant retinal breaks when indicated
• Counsel regarding postoperative symptoms

Cataract surgery does not create the genetic risk but may add further vitreoretinal change in a susceptible eye.

Refractive Surgery

Corneal refractive surgery does not treat the underlying vitreoretinal disorder.

In patients with:

• Very high myopia
• Retinal disease
• Unstable ocular status

laser refractive surgery may provide limited overall benefit.

It is not universally contraindicated solely because of Stickler syndrome, but careful:

Corneal and retinal evaluation is essential.

Sports and Trauma

There is limited evidence that routine activity restriction prevents retinal detachment.

However, avoiding activities with a high risk of:

Blunt ocular trauma

is reasonable, especially in highly susceptible eyes.

Protective eyewear is advisable for:

• Sports
• Occupational hazards

Follow-Up Strategy

Follow-up should be individualized according to:

• Age
• Genotype
• Previous RD
• Peripheral retinal findings
• Family history

Many patients require:

Regular lifelong dilated retinal examinations, often annually or more frequently when risk is high.

When Follow-Up Should Be More Frequent

Closer surveillance is appropriate with:

• Recent retinal symptoms
• Untreated retinal breaks
• Fellow-eye RD
• Rapid vitreoretinal changes
• Early childhood high-risk disease

Symptoms override any routine appointment schedule.

Multidisciplinary Care

Patients may benefit from:

• Retina specialist
• Clinical genetics
• Audiology
• ENT/cleft-palate team
• Orthopedics or rheumatology
• Pediatrics

depending on phenotype.

Genetic Counseling

Counseling should cover:

• Inheritance pattern
• Recurrence risk
• Variable expression
• Testing of relatives
• Reproductive options

Prenatal and preimplantation genetic testing may be possible when the familial pathogenic variant is known.

Expected Visual Outcome

Visual prognosis depends strongly on:

• Retinal detachment occurrence
• Macular involvement
• Surgical success
• Refractive correction
• Amblyopia prevention

A patient without retinal detachment may retain excellent functional vision despite high myopia.

Major Causes of Visual Loss

The most important causes are:

• Retinal detachment
• Amblyopia from uncorrected high myopia
• Cataract
• Glaucoma
• Macular damage after RD

Long-Term Complications

Important ocular complications include:

• Rhegmatogenous retinal detachment
• Giant retinal tear
• Bilateral retinal detachment
• Cataract
• Glaucoma
• High myopia
• Amblyopia
• Proliferative vitreoretinopathy after RD

High-Yield Takeaways

• Stickler syndrome is an inherited collagen disorder characterized ophthalmically by abnormal vitreous, high myopia, peripheral retinal degeneration, and a very high risk of retinal detachment.
• The most common form is autosomal dominant COL2A1-associated type 1 Stickler syndrome.
• COL11A1 causes type 2 disease, while COL11A2 classically causes a nonocular form.
• Autosomal recessive forms can result from COL9A1, COL9A2, and COL9A3 variants.
• Type 1 disease classically has a membranous vitreous phenotype; type 2 often shows a beaded vitreous phenotype.
• High myopia may be present from infancy or early childhood, so early refraction is essential to prevent amblyopia.
• The major ocular threat is rhegmatogenous retinal detachment, which may occur in childhood, involve giant tears, and become bilateral.
• A negative family history does not exclude Stickler syndrome because of variable expression and occasional de novo disease.
• The older statement that COL2A1 ocular disease requires an exon 2 mutation is incorrect; exon 2 variants are instead particularly associated with predominantly ocular phenotypes.
• Important systemic clues include Pierre Robin sequence, cleft or submucous palate, hearing loss, midface hypoplasia, and early arthropathy.
• Routine echocardiographic screening solely for historical concern about mitral valve prolapse is not generally required without clinical indications.
• Diagnosis should include careful examination of the vitreous and entire peripheral retina, not just the macula.
• Genetic testing is now an important part of diagnosis and family counseling.
• First-degree relatives should be considered for ocular examination and genetic evaluation.
• Selected high-risk patients, especially those with COL2A1-associated type 1 disease, may benefit from prophylactic 360-degree retinal treatment; this should be decided with an experienced vitreoretinal specialist.
• Once retinal detachment occurs, repair may be complex because of multiple breaks, giant retinal tears, and proliferative vitreoretinopathy.
• Patients and families must recognize flashes, new floaters, a curtain/shadow, or sudden vision loss as retinal emergencies.
• Lifelong ophthalmic surveillance is essential because retinal risk persists even when vision is currently excellent.

Ophthalmology – Stevens–Johnson Syndrome

What the Disorder Represents

Stevens–Johnson syndrome (SJS) is a rare, life-threatening severe cutaneous adverse reaction characterized by widespread keratinocyte death with epidermal and mucosal epithelial necrosis.

It lies on a spectrum with:

• SJS
• SJS–TEN overlap
• Toxic epidermal necrolysis (TEN)

The eyes are commonly involved, and ocular disease may cause permanent visual disability even when the systemic illness resolves.

The major ophthalmic threats are:

• Severe conjunctival inflammation
• Cicatrization
• Symblepharon
• Lid-margin keratinization
• Limbal stem-cell deficiency
• Chronic severe dry eye
• Corneal ulceration, neovascularization, and scarring

A Major Modern Terminology Correction

Older texts frequently described SJS as:

• “Erythema multiforme major”
• “Bullous erythema multiforme”

These are now considered distinct disorders.

Classic SJS/TEN is most often:

Medication induced

whereas erythema multiforme is more commonly associated with infections such as:

• Herpes simplex virus

and generally has a different clinical course.

How SJS and TEN Are Separated

Classification is based mainly on the percentage of body surface area with:

Epidermal detachment

Stevens–Johnson Syndrome

<10% body surface area

SJS–TEN Overlap

10–30%

Toxic Epidermal Necrolysis

>30%

They are best regarded as:

Different severities of the same disease spectrum.

How Often It Occurs

SJS/TEN is rare.

Incidence varies by:

• Population
• Medication exposure
• Genetic background
• HIV prevalence

The condition can occur at any age.

Who Is at Increased Risk

Risk is increased by:

• Previous SJS/TEN
• HIV infection
• Malignancy
• Polypharmacy
• Certain high-risk medications
• Particular HLA genotypes
• Some autoimmune disorders

The most important preventive principle is:

Never re-expose a patient to the suspected culprit drug or a closely related high-risk drug without specialist guidance.

What Causes the Tissue Injury

SJS/TEN is not primarily an immune-complex disease.

The central mechanism involves:

Drug-specific cytotoxic immune activation → massive keratinocyte apoptosis → epidermal and mucosal epithelial necrosis

Important mediators include:

• Cytotoxic T lymphocytes
• Natural killer cells
• Granulysin
• Fas/Fas-ligand pathways
• Other pro-apoptotic cytokines

Why the Eye Is So Vulnerable

The ocular surface is lined by rapidly regenerating epithelium.

Acute epithelial destruction affects:

• Conjunctiva
• Cornea
• Lid margins
• Meibomian gland orifices

Healing may occur through:

Fibrosis and cicatrization

which creates many of the devastating chronic complications.

The Most Important Triggers

Most adult SJS/TEN cases are associated with:

Medications

High-risk drugs include:

• Allopurinol
• Sulfonamide antibiotics
• Carbamazepine
• Lamotrigine
• Phenytoin
• Phenobarbital
• Nevirapine
• Oxicam NSAIDs

Other medications can also trigger the disease.

Timing After Drug Exposure

SJS/TEN typically develops within:

The first several weeks after starting a new medication

Risk is highest during the early treatment period.

A medication started many months or years previously without recent interruption is generally less likely to be the culprit than a newly introduced drug.

Important Infectious Mimics

Infections can produce severe mucositis resembling SJS.

In particular, Mycoplasma pneumoniae and other respiratory infections may cause:

Reactive infectious mucocutaneous eruption (RIME)

This is now generally considered distinct from classic drug-induced SJS/TEN.

Genetic Susceptibility

Strong HLA–drug associations are recognized.

Important examples include:

• HLA-B*15:02 with carbamazepine-associated SJS/TEN in several Asian populations
• HLA-B*58:01 with allopurinol severe cutaneous adverse reactions
• HLA-A*31:01 with carbamazepine hypersensitivity in some populations

Genetic screening is recommended in selected high-risk populations before certain medications according to:

• Ancestry
• Drug
• Local guidelines

Typical Early Symptoms

Patients often develop a prodrome resembling a severe viral illness:

• Fever
• Malaise
• Sore throat
• Cough
• Myalgia
• Headache

Ocular symptoms may begin early with:

• Burning
• Foreign-body sensation
• Photophobia
• Redness
• Tearing

How the Skin Disease Evolves

Patients develop:

• Tender erythematous macules
• Dusky or purpuric lesions
• Blistering
• Epidermal detachment

The skin may become extremely painful.

A positive:

Nikolsky sign

may be present, with epidermal separation after gentle pressure.

Mucosal Involvement

Severe mucosal disease commonly affects:

• Oral mucosa
• Eyes
• Genital tract
• Nasal mucosa
• Respiratory tract

Patients may have:

• Painful oral erosions
• Difficulty eating or drinking
• Dysuria
• Respiratory involvement

Acute Ocular Manifestations

Ocular disease may range from mild conjunctivitis to severe epithelial necrosis.

Findings include:

• Conjunctival hyperemia
• Chemosis
• Mucous discharge
• Conjunctival epithelial defects
• Pseudomembranes
• Corneal epithelial defects
• Lid-margin ulceration
• Early symblepharon

Why Eyelid Margin Disease Is Important

Ulceration of the lid margin may heal with:

• Keratinization
• Meibomian gland destruction
• Trichiasis
• Cicatricial entropion

These chronic lid abnormalities can continuously traumatize the cornea.

Pseudomembranes

Conjunctival pseudomembranes may form during the acute phase.

They should be:

Carefully removed when clinically appropriate

because retained inflammatory material can promote:

• Adhesion formation
• Cicatrization
• Symblepharon

Symblepharon Formation

Opposing raw conjunctival surfaces can adhere, producing:

Symblepharon

which may cause:

• Forniceal shortening
• Restricted ocular motility
• Tear-film abnormalities
• Chronic surface disease

Early prevention is therefore essential.

Corneal Disease During the Acute Phase

Corneal involvement may include:

• Punctate epithelial keratopathy
• Large epithelial defects
• Stromal inflammation
• Rare ulceration

Severe epithelial injury increases the later risk of:

Limbal stem-cell deficiency.

How Ocular Severity Should Be Assessed

Patients with suspected SJS/TEN should receive:

Early ophthalmology assessment

ideally within the first day of hospitalization.

The examination should document:

• Lid-margin epithelial loss
• Conjunctival epithelial defects
• Pseudomembranes
• Corneal involvement
• Forniceal shortening
• Symblepharon

Moderate-to-severe ocular disease may progress quickly, so:

Daily examination is often appropriate during the acute phase.

How the Systemic Diagnosis Is Established

Diagnosis is primarily clinical, supported by:

• Medication history
• Skin examination
• Mucosal involvement
• Percentage of epidermal detachment

Skin biopsy may be performed when diagnosis is uncertain.

What the Biopsy Shows

Histopathology typically demonstrates:

• Full-thickness epidermal necrosis
• Subepidermal separation
• Sparse dermal inflammatory infiltrate
• Extensive keratinocyte apoptosis

These findings help distinguish SJS/TEN from other blistering disorders.

Important Diagnostic Alternatives

The differential includes:

• Erythema multiforme
• RIME
• Staphylococcal scalded skin syndrome
• Acute generalized exanthematous pustulosis
• Drug reaction with eosinophilia and systemic symptoms
• Pemphigus vulgaris
• Paraneoplastic pemphigus
• Mucous membrane pemphigoid
• Linear IgA bullous dermatosis

The First Systemic Treatment Step

The suspected offending medication should be:

Stopped immediately

This is one of the most important interventions affecting outcome.

Unnecessary medications should also be minimized.

Where Patients Should Be Managed

SJS/TEN is a:

Medical emergency

and generally requires hospitalization.

Management may occur in:

• Intensive care unit
• Burn unit
• Specialized dermatology unit

depending on severity and local expertise.

Core Supportive Treatment

Systemic management includes:

• Fluid and electrolyte replacement
• Temperature control
• Nutritional support
• Pain control
• Wound care
• Infection surveillance
• Respiratory monitoring

Supportive care remains fundamental regardless of which systemic immunomodulatory treatment is used.

Why Prophylactic Antibiotics Are Not Routine

Broad systemic antibiotics are generally not given solely to prevent infection.

They are reserved for:

Documented or strongly suspected infection

because unnecessary antibiotics can:

• Promote resistance
• Cause additional adverse reactions
• Potentially complicate culprit-drug assessment

Assessing Systemic Severity

Severity and mortality risk can be estimated using tools such as:

SCORTEN

which incorporates systemic clinical and laboratory factors.

Higher scores correlate with increased mortality.

Systemic Immunomodulatory Therapy

There is no universally accepted single regimen worldwide.

Treatments used in specialist centers include:

• Systemic corticosteroids
• Cyclosporine
• Etanercept
• IV immunoglobulin in selected settings
• Combination regimens

Choice depends on:

• Disease severity
• Timing
• Comorbidities
• Center experience

Important Modern Perspective on Systemic Therapy

Older recommendations favored prolonged high-dose steroids or IVIG relatively broadly.

Current practice is more individualized.

Evidence increasingly supports selected use of:

• Cyclosporine
• Etanercept

while corticosteroids remain widely used early in some protocols.

IVIG has:

Variable evidence and is not uniformly effective as monotherapy.

Immediate Eye-Surface Management

Acute ocular treatment may include:

• Frequent preservative-free lubrication
• Topical corticosteroid
• Topical antibiotic when epithelial defects are present or infection risk is significant
• Pseudomembrane removal
• Forniceal sweeping when needed

The regimen is individualized according to surface severity.

Role of Topical Corticosteroids

Topical corticosteroids are commonly used during the acute inflammatory stage to reduce:

• Conjunctival inflammation
• Cicatrization

They require ophthalmic monitoring for:

• Infection
• IOP elevation
• Epithelial healing

The Major Modern Advance – Early Amniotic Membrane

One of the most important changes in modern ophthalmic management is:

Early amniotic membrane transplantation (AMT)

for moderate-to-severe acute ocular involvement.

AMT should ideally be considered:

Within the first several days, generally within the first week

before extensive cicatrization develops.

Why Amniotic Membrane Is Used

Amniotic membrane can:

• Reduce ocular surface inflammation
• Promote epithelial healing
• Protect exposed conjunctiva
• Reduce scar formation
• Lower the risk of severe chronic cicatricial disease

What Must Be Covered

For severe SJS/TEN, effective AMT should ideally cover:

• Cornea
• Bulbar conjunctiva
• Palpebral conjunctiva
• Lid margins
• Fornices

Treating only the cornea may leave the patient vulnerable to severe conjunctival and lid-margin scarring.

Methods of Amniotic Membrane Placement

Approaches include:

• Sutured AMT
• Adhesive techniques
• Ring-supported membrane systems

The choice depends on:

• Disease severity
• Patient stability
• Local expertise

Why Waiting Can Be Harmful

Once mature conjunctival fibrosis and lid-margin keratinization develop:

AMT can no longer reverse established cicatricial damage.

This is why early ophthalmology involvement is so important.

Preventing Adhesions

During the acute phase, management may include:

• Gentle removal of pseudomembranes
• Forniceal sweeping
• Symblepharon rings in selected patients
• AMT

These strategies aim to preserve:

Forniceal depth and conjunctival mobility.

Chronic Dry Eye After SJS/TEN

Long-term tear dysfunction may result from:

• Lacrimal gland injury
• Conjunctival goblet-cell loss
• Meibomian gland destruction
• Cicatricial lid abnormalities

This can cause:

Severe aqueous-deficient and evaporative dry eye.

Chronic Eyelid Problems

Common late abnormalities include:

• Trichiasis
• Distichiasis
• Cicatricial entropion
• Lagophthalmos
• Lid-margin keratinization

These abnormalities can produce continuous mechanical trauma to the cornea.

Lid-Margin Keratinization

Posterior lid-margin keratinization is particularly damaging because keratinized epithelium repeatedly rubs across the:

Corneal surface during blinking

and can cause:

• Persistent epithelial defects
• Corneal neovascularization
• Scarring

Treating Chronic Lid-Margin Keratinization

Options include:

• Protective scleral lenses
• Epilation for focal lashes
• Lid surgery
• Mucous membrane grafting for significant posterior lid-margin keratinization

Mucous membrane grafting can replace the keratinized surface with healthier nonkeratinized epithelium.

Severe Chronic Ocular Surface Disease

Long-term therapy may include:

• Preservative-free artificial tears
• Lubricating ointment
• Autologous serum tears
• Tear-conservation strategies
• Management of lid abnormalities
• Scleral lenses

Role of Scleral Lenses

Large-diameter scleral lenses, including:

PROSE-type devices

can provide major functional benefit by creating a fluid reservoir over the cornea.

They may improve:

• Pain
• Vision
• Epithelial protection
• Photophobia

Limbal Stem-Cell Deficiency

Severe acute epithelial destruction may damage the limbus, causing:

Limbal stem-cell deficiency

Signs include:

• Conjunctivalization of the cornea
• Persistent epithelial instability
• Neovascularization
• Corneal opacity

This is one of the most difficult chronic consequences to treat.

Why Conventional Corneal Transplantation Often Fails

A standard penetrating keratoplasty may fail when the ocular surface remains:

• Dry
• Inflamed
• Keratinized
• Stem-cell deficient

Therefore surface rehabilitation should generally precede consideration of corneal transplantation.

Advanced Visual Rehabilitation

Selected severe cases may require:

• Limbal stem-cell transplantation
• Keratolimbal allograft
• Keratoprosthesis

These procedures are complex and require specialized ocular surface expertise.

Corneal Infection Risk

Chronic epithelial defects and severe dry eye increase risk for:

Microbial keratitis

Patients should seek urgent care for:

• New pain
• Increased redness
• Photophobia
• Sudden decline in vision
• Corneal opacity

Other Long-Term Ocular Complications

Late complications include:

• Symblepharon
• Forniceal shortening
• Dry eye
• Trichiasis
• Entropion
• Keratinization
• Corneal neovascularization
• Corneal scarring
• Persistent epithelial defects
• Limbal stem-cell deficiency
• Infectious keratitis
• Severe permanent visual loss

Long-Term Systemic Follow-Up

Patients should maintain a clear record of:

• Culprit medication
• Suspected cross-reactive medications
• Date and severity of reaction

The offending drug should be listed prominently as a:

Severe life-threatening allergy.

Why Rechallenge Is Dangerous

Re-exposure to the causative medication can trigger:

Rapid and potentially more severe recurrence

Therefore intentional drug rechallenge is generally avoided.

Expected Systemic Outcome

Mortality depends primarily on:

• Extent of epidermal detachment
• Age
• Comorbidities
• Systemic severity

SJS generally has lower mortality than TEN, but both can be life-threatening.

Expected Visual Outcome

Visual prognosis depends heavily on:

• Severity of acute ocular involvement
• Early ophthalmic treatment
• Extent of lid-margin injury
• Development of conjunctival cicatrization
• Limbal stem-cell damage

Early ocular intervention, particularly:

Timely amniotic membrane treatment when indicated

can substantially reduce severe chronic surface disease.

High-Yield Takeaways

• SJS and TEN are severe mucocutaneous adverse reactions characterized by extensive keratinocyte apoptosis and epithelial necrosis.
• SJS involves <10% epidermal detachment, SJS–TEN overlap 10–30%, and TEN >30%.
• SJS/TEN is distinct from erythema multiforme, despite older terminology linking them.
• Most adult cases are medication related.
• Important culprit drugs include allopurinol, sulfonamide antibiotics, carbamazepine, lamotrigine, phenytoin, phenobarbital, nevirapine, and oxicam NSAIDs.
• Strong pharmacogenetic associations include HLA-B*15:02 with carbamazepine and HLA-B*58:01 with allopurinol in susceptible populations.
• Respiratory infection-associated mucositis, especially from Mycoplasma, is increasingly classified as RIME rather than classic SJS.
• The first systemic treatment step is immediate withdrawal of the culprit drug.
• SJS/TEN requires hospital-level multidisciplinary care, often in an ICU or burn unit.
• Ocular assessment should occur very early, because surface damage may progress rapidly.
• Acute ocular signs include conjunctival epithelial defects, pseudomembranes, lid-margin ulceration, corneal epithelial defects, and early symblepharon.
• Early amniotic membrane transplantation is a major modern intervention for moderate-to-severe ocular disease and is most useful when performed before established cicatrization.
• Pseudomembrane removal, lubrication, topical anti-inflammatory therapy, and prevention of conjunctival adhesions are important components of acute care.
• Chronic ocular disease may include severe dry eye, symblepharon, trichiasis, cicatricial entropion, lid-margin keratinization, corneal neovascularization, and limbal stem-cell deficiency.
• Posterior lid-margin keratinization can be treated with mucous membrane grafting in selected patients.
• Scleral lenses/PROSE devices can markedly improve comfort and vision in chronic severe ocular surface disease.
• Conventional corneal transplantation alone often performs poorly unless the underlying ocular surface has first been rehabilitated.
• The best chance of preserving long-term vision comes from rapid systemic recognition plus aggressive early ocular-surface protection.

Ophthalmology – Steroid-Induced Glaucoma

What the Disorder Represents

Steroid-induced glaucoma is a secondary open-angle glaucoma caused by corticosteroid-related reduction in aqueous outflow through the trabecular meshwork.

The sequence is:

Corticosteroid exposure → increased trabecular outflow resistance → elevated IOP → glaucomatous optic nerve damage if sufficiently severe or prolonged

An important distinction is:

• Steroid-induced ocular hypertension = IOP elevation without glaucomatous damage
• Steroid-induced glaucoma = IOP elevation with characteristic optic neuropathy and/or visual-field loss

Which Steroids Can Cause It

Virtually any corticosteroid route can produce an IOP response, including:

• Topical ophthalmic drops
• Periocular injections
• Intravitreal injections
• Intravitreal steroid implants
• Systemic corticosteroids
• Inhaled corticosteroids
• Intranasal corticosteroids
• Dermatologic preparations, particularly when applied around the eyelids

Risk varies considerably according to:

• Steroid potency
• Dose
• Duration
• Route
• Individual susceptibility

Which Routes Carry the Greatest Ocular Risk

The largest and most prolonged IOP elevations are often seen with:

• Intravitreal corticosteroids
• Sustained-release intraocular steroid implants
• Periocular depot steroids

Topical ophthalmic steroids are also a common cause because they are frequently prescribed.

Systemic, inhaled, intranasal, and dermatologic formulations generally carry lower ocular risk but can still cause clinically important IOP elevation in susceptible patients.

What Is a Steroid Responder?

A steroid responder is a patient who develops a clinically meaningful rise in IOP after corticosteroid exposure.

Responses range from:

• Minimal
• Moderate
• Marked

A small proportion of the general population are:

High steroid responders

and may develop substantial IOP elevations even with relatively short treatment courses.

Who Is Most Susceptible

Risk is increased in patients with:

• Primary open-angle glaucoma
• Ocular hypertension
• First-degree family history of glaucoma
• Previous steroid-induced IOP elevation
• High baseline IOP
• High myopia
• Diabetes mellitus
• Young children
• Older adults

Patients with advanced pre-existing glaucoma are particularly vulnerable because even a moderate additional IOP rise may cause further damage.

Why Children Require Special Attention

Children can develop:

• Rapid
• Large
• Occasionally asymptomatic

IOP elevations after topical or systemic corticosteroids.

This is particularly important when steroids are prescribed for:

• Uveitis
• Vernal keratoconjunctivitis
• Postoperative inflammation
• Dermatologic disease around the eyes

IOP monitoring should not be omitted simply because the patient is young.

How Steroids Raise IOP

Corticosteroids act through glucocorticoid receptors in trabecular meshwork cells and produce several changes that reduce aqueous outflow.

These include:

• Increased extracellular matrix deposition
• Altered actin cytoskeleton
• Reduced trabecular meshwork phagocytosis
• Reduced degradation of extracellular material
• Altered cell-cell and cell-matrix adhesion
• Increased expression of proteins such as myocilin

The result is:

Higher resistance to aqueous passage through the conventional outflow pathway.

Relationship to Myocilin

Corticosteroids can increase:

MYOC/myocilin expression

in trabecular meshwork cells.

MYOC mutations are also associated with:

• Juvenile open-angle glaucoma
• Some adult-onset open-angle glaucoma

However, steroid-induced glaucoma itself is not simply a MYOC mutation disorder.

When IOP Usually Starts to Rise

With topical ophthalmic corticosteroids, IOP commonly begins to rise after approximately:

2–6 weeks

although elevation can occur:

• Within days in highly susceptible patients
• Much later during chronic treatment

Depot or sustained-release intraocular steroid preparations may cause elevation:

Weeks to months after administration

and the effect may persist for a prolonged period.

Why Timing Can Be Misleading

A patient may develop steroid-related IOP elevation even after:

• Months of apparently safe treatment
• Repeated previous steroid courses without difficulty

Therefore a normal early IOP does not eliminate later risk.

What Happens After Steroids Are Stopped

After discontinuing topical corticosteroids, IOP often returns toward baseline over:

Days to several weeks

However, normalization may take longer after:

• Long-term exposure
• Depot injections
• Intravitreal implants

Some patients with underlying glaucoma may continue to require treatment even after the steroid effect resolves.

Why Route and Molecule Matter

More potent ocular steroids generally have a greater tendency to raise IOP.

Higher-risk agents include:

• Dexamethasone
• Prednisolone acetate
• Difluprednate

Agents with a generally lower propensity for IOP elevation include:

• Loteprednol
• Fluorometholone

However:

No corticosteroid is completely free of steroid-response risk.

Why Loteprednol Is Often Chosen

Loteprednol is designed to undergo rapid metabolism after exerting its anti-inflammatory action.

This tends to produce:

A lower average risk of clinically significant IOP elevation

than stronger ketone corticosteroids such as prednisolone or dexamethasone.

It is still capable of raising IOP in susceptible patients.

What Patients Usually Notice

Most patients with steroid-induced ocular hypertension are:

Asymptomatic

even when IOP is significantly elevated.

When IOP becomes very high, symptoms may include:

• Ocular discomfort
• Headache
• Blurred vision
• Halos

But absence of symptoms provides:

No reassurance that the IOP is normal.

History That Should Always Be Taken

Ask specifically about every possible corticosteroid source:

• Eye drops
• Intravitreal injections
• Periocular injections
• Oral steroids
• IV steroids
• Inhalers
• Nasal sprays
• Skin creams
• Joint injections
• Steroid implants

Patients may not recognize inhalers or skin creams as:

Steroid exposure.

What the Examination Usually Shows

Typical findings include:

• Elevated IOP compared with baseline
• Open anterior chamber angle
• Otherwise relatively quiet anterior segment if there is no underlying inflammatory disease

If glaucoma has developed, the optic nerve may show:

• Neuroretinal rim thinning
• Focal notching
• RNFL defects
• Disc hemorrhage

Gonioscopy Findings

Gonioscopy typically shows:

An open angle

because the mechanism is increased trabecular resistance rather than angle closure.

Gonioscopy is important to exclude:

• Angle closure
• Neovascularization
• Trauma-related angle recession
• Other secondary glaucoma mechanisms

Optic Nerve Evaluation

Look for classic glaucomatous abnormalities including:

• Focal rim thinning
• Superior or inferior notching
• Increased vertical cup-to-disc ratio
• RNFL defects
• Disc hemorrhage

The appearance is generally indistinguishable from:

Primary open-angle glaucoma.

OCT Assessment

Modern structural evaluation includes:

• Peripapillary RNFL OCT
• Macular ganglion cell/inner plexiform layer analysis
• Optic nerve photography when useful

These help establish whether elevated IOP has already caused:

Glaucomatous structural damage.

Visual Field Testing

Standard automated perimetry should be performed when:

• IOP elevation is significant
• The optic nerve appears suspicious
• Pre-existing glaucoma is present

Typical field defects include:

• Nasal step
• Paracentral defect
• Arcuate scotoma

Why Pachymetry Is Useful

Central corneal thickness affects interpretation of:

Applanation IOP

but should not be used as a simple mathematical correction factor.

It contributes to overall glaucoma risk assessment rather than providing a precise “corrected IOP.”

Distinguishing Steroid-Induced Glaucoma From POAG

The two conditions can look almost identical.

Clues favoring a steroid effect include:

• Temporal relationship to corticosteroid exposure
• Previous normal IOP
• IOP reduction after steroid reduction or cessation
• Marked elevation during steroid therapy

Some patients have both:

Underlying POAG plus an additional steroid response.

Distinguishing It From Uveitic Glaucoma

This is a common diagnostic challenge.

A patient being treated for uveitis may have high IOP because of:

Steroid Effect

• Usually open angle
• Often develops after steroid exposure
• Eye may be relatively quiet

Active Uveitis

IOP elevation may result from:

• Trabeculitis
• Inflammatory debris
• Peripheral anterior synechiae
• Pupillary block
• Other inflammatory mechanisms

In many patients:

Both mechanisms contribute simultaneously.

Do Not Stop Necessary Steroids Reflexively

If the patient is being treated for:

• Severe uveitis
• Scleritis
• Postoperative inflammation
• Systemic autoimmune disease

abrupt steroid cessation may be harmful.

The goal is instead to balance:

Inflammatory control and IOP control.

First Management Step

When medically possible:

Reduce, discontinue, or replace the corticosteroid

with a less IOP-provoking alternative.

Possible strategies include:

• Lower dose
• Lower frequency
• Shorter course
• Switch to loteprednol or another lower-risk steroid
• Introduce steroid-sparing therapy for chronic inflammatory disease

This should be coordinated with the clinician treating the underlying condition.

First-Line IOP-Lowering Medication

Treatment generally follows principles used for other open-angle glaucomas.

Common options include:

• Topical beta-blockers
• Topical carbonic anhydrase inhibitors
• Alpha-2 agonists
• Prostaglandin analogues

Choice depends on:

• Magnitude of IOP elevation
• Comorbidities
• Underlying ocular inflammation

Beta-Blockers

Examples include:

• Timolol
• Betaxolol

These reduce aqueous production.

Avoid or use cautiously in patients with:

• Asthma
• Significant COPD
• Bradycardia
• Heart block

Topical Carbonic Anhydrase Inhibitors

Useful agents include:

• Dorzolamide
• Brinzolamide

They reduce aqueous secretion and are frequently used in:

• Steroid-induced ocular hypertension
• Uveitic glaucoma

Alpha-2 Agonists

Brimonidine can provide additional IOP reduction.

Potential limitations include:

• Allergic follicular conjunctivitis
• Fatigue
• Dry mouth

It should generally be avoided in:

Young children

because of CNS depression risk.

Prostaglandin Analogues

Agents such as:

• Latanoprost
• Travoprost
• Bimatoprost
• Tafluprost

are effective IOP-lowering medications and can be used in many patients with steroid-induced glaucoma.

Older concerns that prostaglandins routinely trigger:

• Uveitis
• CME

appear to have been overstated, although caution may still be reasonable in selected patients with:

• Active severe inflammation
• Recent complicated intraocular surgery
• Prior herpetic keratouveitis

Combination Drops

Fixed combinations can improve adherence when multiple medications are required.

Examples include:

• Dorzolamide/timolol
• Brimonidine/timolol
• Brinzolamide/brimonidine

Choice should be individualized.

When Oral Acetazolamide Is Useful

For substantial or rapidly rising IOP, systemic carbonic anhydrase inhibition may be used temporarily.

Acetazolamide can rapidly reduce aqueous production.

Use cautiously in patients with:

• Renal impairment
• Electrolyte disturbances
• Sulfonamide-related severe drug reactions
• Certain metabolic conditions

Hyperosmotic Therapy

Agents such as IV mannitol are:

Not routine therapy for chronic steroid-induced glaucoma

but may be considered for a severe acute IOP crisis when rapid temporary reduction is required.

Selective Laser Trabeculoplasty

SLT can be effective in steroid-induced ocular hypertension or glaucoma, particularly when:

• The angle is open
• Chronic corticosteroid exposure must continue
• Medication burden is high

It can reduce dependence on topical therapy.

Why SLT Can Be Especially Useful

The trabecular meshwork is the primary site of steroid-induced outflow resistance.

SLT can therefore improve:

Trabecular aqueous outflow

without requiring steroid withdrawal.

Its effectiveness varies among patients.

When Surgery Is Needed

Surgery is considered when IOP remains uncontrolled despite:

• Steroid modification
• Medical therapy
• Laser treatment

or when optic nerve damage is advancing.

Surgical Options

Depending on severity and ocular anatomy, options may include:

• Trabeculectomy
• Glaucoma drainage device
• Angle-based procedures/MIGS in selected patients
• Goniotomy or trabeculotomy, particularly in selected pediatric cases

More severe or inflammatory cases may require:

Trabeculectomy or tube-shunt surgery.

MIGS in Steroid-Induced Glaucoma

Because the angle is usually open, selected patients may benefit from procedures targeting the conventional outflow pathway.

These may include:

• Trabecular bypass
• Goniotomy
• Trabeculotomy-based procedures

They are most appropriate when:

• Disease is not extremely advanced
• Target IOP is compatible with MIGS capability

Monitoring Before Starting Steroids

Whenever significant or prolonged corticosteroid therapy is planned, ideally document:

• Baseline IOP
• Optic nerve status
• Glaucoma history

Baseline OCT and visual fields are useful when:

• Glaucoma already exists
• Long-term potent steroid therapy is anticipated

Monitoring After Starting Topical Steroids

A practical approach is to check IOP:

• At baseline when possible
• After approximately 2–4 weeks
• Again during continued therapy

High-risk patients may need:

Earlier and more frequent monitoring.

There is no single schedule appropriate for every patient.

Monitoring After Depot or Intravitreal Steroids

Patients receiving:

• Intravitreal triamcinolone
• Dexamethasone implant
• Fluocinolone implants
• Periocular depot steroids

may require:

Longer and more frequent surveillance

because IOP elevation can be delayed and prolonged.

Follow-up should reflect the known pharmacologic duration of the particular preparation.

Patients With Existing Glaucoma

If the patient already has glaucoma, management should aim to maintain IOP at or below the individual’s:

Established target pressure

rather than accepting a generic value such as 30 mm Hg.

Even relatively modest IOP elevation may be unacceptable in advanced disease.

Why a Fixed IOP Threshold Is Misleading

Older recommendations sometimes used a universal threshold such as:

IOP <30 mm Hg

for patients without apparent damage.

Modern glaucoma care is more individualized.

Treatment intensity depends on:

• Baseline IOP
• Duration of elevation
• Optic nerve susceptibility
• Existing glaucoma
• Rate of progression
• Age and life expectancy

How Treatment Response Is Followed

Monitor:

• IOP
• Optic nerve appearance
• RNFL/GCC OCT
• Visual fields
• Medication adherence
• Steroid dose and route

In patients on long-term corticosteroids, monitoring should continue even after an initially normal response.

When Urgent Treatment Is Needed

More urgent intervention is appropriate when there is:

• Very high IOP
• Rapid rise from baseline
• Advanced glaucoma
• New visual field loss
• Progressive OCT damage
• Corneal edema from high pressure

Expected Outcome

Prognosis is generally excellent when:

• The IOP rise is detected early
• Steroid exposure is modified
• Pressure is adequately controlled

Steroid-induced ocular hypertension is often:

Reversible

but glaucomatous optic nerve damage is:

Permanent.

When IOP May Remain Elevated

Persistent glaucoma is more likely when:

• Steroid exposure was prolonged
• IOP was markedly elevated
• The patient already had POAG
• Structural optic nerve damage developed

Such patients may require lifelong glaucoma treatment.

Potential Complications

Untreated or inadequately controlled disease can cause:

• RNFL loss
• Progressive optic nerve cupping
• Arcuate visual field defects
• Paracentral field loss
• Peripheral field constriction
• Irreversible visual impairment

High-Yield Takeaways

• Steroid-induced glaucoma is a secondary open-angle glaucoma caused by corticosteroid-related reduction in trabecular aqueous outflow.
• Elevated IOP without optic nerve damage is better termed steroid-induced ocular hypertension.
• Any corticosteroid route can cause an IOP rise, including topical, periocular, intravitreal, systemic, inhaled, intranasal, and periocular dermatologic preparations.
• Major risk factors include pre-existing POAG, ocular hypertension, family history of glaucoma, previous steroid response, high myopia, diabetes, and young age.
• Topical steroid-associated IOP elevation most commonly appears after 2–6 weeks, but susceptible patients may respond much sooner.
• Intravitreal injections and long-acting steroid implants can produce delayed and prolonged IOP elevation.
• More potent steroids such as dexamethasone, prednisolone acetate, and difluprednate generally carry greater risk than agents such as loteprednol.
• The mechanism is primarily increased trabecular meshwork resistance from extracellular matrix, cytoskeletal, and cellular changes.
• The anterior chamber angle is typically open on gonioscopy.
• The optic nerve and visual-field pattern are essentially indistinguishable from primary open-angle glaucoma.
• In uveitis, always distinguish steroid response from inflammation-related IOP elevation; both can coexist.
• The first management step is to reduce, stop, or switch the corticosteroid when medically safe, but necessary anti-inflammatory therapy should not be withdrawn indiscriminately.
• Topical glaucoma therapy commonly includes beta-blockers, carbonic anhydrase inhibitors, alpha-2 agonists, and prostaglandin analogues.
• SLT is an effective option in selected patients, particularly when corticosteroid treatment must continue.
• Refractory disease may require MIGS, trabeculectomy, or a glaucoma drainage device, depending on disease severity.
• Patients starting prolonged ocular corticosteroids should ideally have a baseline IOP and subsequent IOP monitoring, with closer surveillance for high-risk patients.
• A fixed IOP threshold such as 30 mm Hg is not an appropriate universal treatment target; management should be based on individual glaucoma risk and target IOP.
• Steroid-induced IOP elevation may reverse after treatment is stopped, but glaucomatous optic nerve damage is irreversible, making early detection essential.

Ophthalmology – Stargardt Disease

What the Disorder Represents

Stargardt disease is the most common inherited juvenile macular dystrophy and is characterized by progressive dysfunction and degeneration of the:

• Photoreceptors
• Retinal pigment epithelium (RPE)
• Macula

The classic form is:

ABCA4-associated Stargardt disease (STGD1)

and is usually inherited in an:

Autosomal recessive pattern.

Although classically presenting in childhood or adolescence, onset can range from:

• Early childhood
• Teenage years
• Adulthood
• Occasionally late adulthood

Earlier onset generally predicts a more severe course.

How Common It Is

Stargardt disease is uncommon but is the most frequent inherited macular dystrophy.

Estimated prevalence is approximately:

1 in 8,000–10,000 people

although estimates vary by population.

The Main Genetic Cause

The classic disorder is caused by biallelic pathogenic variants in:

ABCA4

on chromosome:

1p22

ABCA4 encodes an ATP-binding cassette transporter located in photoreceptor outer-segment disc membranes.

How It Is Inherited

Classic STGD1 is:

Autosomal recessive

Therefore an affected patient typically has:

• Two pathogenic ABCA4 variants
• One inherited from each parent

Parents are often unaffected carriers.

Siblings have a:

25% recurrence risk when both parents are carriers, assuming classic autosomal recessive inheritance.

Why a Strong Family History Is Often Absent

Because the disorder is usually autosomal recessive:

• Parents are typically unaffected
• Multiple generations may appear unaffected
• Only siblings may be affected

Therefore:

Absence of a family history does not argue strongly against Stargardt disease.

Stargardt-Like Dominant Disorders

Not every Stargardt-like phenotype is caused by ABCA4.

Autosomal dominant macular dystrophies that can resemble Stargardt include disorders associated with:

• ELOVL4
• PROM1
• PRPH2 and other genes

These are genetically distinct from classic:

ABCA4-associated STGD1.

Why ABCA4 Dysfunction Damages the Retina

ABCA4 normally helps remove retinoid by-products from photoreceptor outer-segment discs.

When ABCA4 function is impaired:

Retinoid intermediates accumulate → toxic bisretinoids form → lipofuscin accumulates in the RPE

Important toxic fluorophores include:

A2E and related bisretinoids

which contribute to:

• Oxidative stress
• RPE dysfunction
• Photoreceptor loss

Why the Macula Is Especially Vulnerable

The macula has:

• Very high photoreceptor density
• High visual-cycle activity
• High metabolic demand

This makes the central retina especially susceptible to:

Bisretinoid accumulation and RPE-photoreceptor injury.

What “Fundus Flavimaculatus” Means

Fundus flavimaculatus is an older descriptive term referring to the characteristic widespread yellow-white flecks associated with Stargardt disease.

Historically it was sometimes used for:

• Later-onset disease
• More widespread flecks

Today it is generally regarded as part of the:

Stargardt/ABCA4 disease spectrum

rather than a completely separate condition.

Typical Symptoms

Patients usually present with:

• Progressive central visual loss
• Difficulty reading
• Trouble recognizing faces
• Central or paracentral scotoma
• Reduced contrast sensitivity
• Dyschromatopsia

Photophobia may occur.

Peripheral vision is often relatively preserved early.

How Early Disease Can Be Missed

In early disease, the fundus may appear:

Nearly normal

despite significant central visual complaints.

This historically led some patients to be incorrectly suspected of:

• Functional visual loss
• Malingering

Modern OCT and fundus autofluorescence greatly reduce this diagnostic problem.

Early Macular Appearance

The earliest visible changes may include:

• Subtle foveal RPE mottling
• Loss of the normal foveal reflex
• Mild central pigmentary disturbance

A classic description is:

“Beaten-bronze” macular appearance

although this is not present in every patient.

Characteristic Flecks

The classic lesions are:

Yellow-white pisciform flecks

located at the level of the:

• RPE
• Outer retina

They may appear:

• Fish-shaped
• Irregular
• Round
• Elongated

and often extend beyond the macula.

How Flecks Change Over Time

Flecks may initially appear:

• Bright
• Yellow-white
• Hyperautofluorescent

As they involute they may become:

• Less visible
• Hypoautofluorescent
• Associated with local RPE atrophy

Advanced Macular Disease

With progression, patients can develop:

• Macular RPE atrophy
• Photoreceptor loss
• Geographic atrophy-like lesions
• Bull’s-eye maculopathy

Central atrophy may become extensive.

Foveal Sparing

Some patients, especially with later-onset disease, develop:

Foveal sparing

where parafoveal atrophy surrounds a relatively preserved central fovea.

These patients may retain:

• Better visual acuity
• Central fixation

for longer than expected from the extent of surrounding atrophy.

The Most Useful Modern Imaging Tests

The key investigations are:

• Fundus autofluorescence (FAF)
• Optical coherence tomography (OCT)

They provide far more information than fluorescein angiography alone.

Fundus Autofluorescence Findings

FAF is particularly useful because lipofuscin-related fluorophores accumulate within the RPE.

Typical findings include:

• Hyperautofluorescent flecks
• Hypoautofluorescent areas of established RPE atrophy
• Mixed speckled autofluorescence around the macula

FAF often shows:

More extensive disease than is visible clinically.

Why Hyperautofluorescence Occurs

Areas of increased autofluorescence generally correspond to:

• Increased lipofuscin-related fluorophores
• Stressed RPE

whereas:

Hypoautofluorescence

usually corresponds to:

• RPE loss
• Advanced atrophy

OCT Findings

Spectral-domain OCT can demonstrate:

• Ellipsoid-zone disruption
• Outer-segment loss
• Outer nuclear layer thinning
• RPE irregularity
• Progressive outer retinal atrophy

Advanced disease may show complete loss of:

• Photoreceptors
• RPE

within the affected macula.

OCT as a Progression Marker

Serial OCT can document progression through changes in:

• Ellipsoid-zone width
• Outer retinal thickness
• RPE atrophy
• Foveal preservation

It is especially useful for monitoring:

Structural disease progression over time.

The Classic “Dark Choroid”

Fluorescein angiography may demonstrate:

Dark or silent choroid

where the normal background choroidal fluorescence is reduced.

This occurs because lipofuscin-rich RPE blocks:

Choroidal fluorescence.

How Useful Is the Dark Choroid?

The dark choroid is:

• Characteristic
• Historically important

but it is:

Not present in every patient

and its absence does not exclude Stargardt disease.

FA is therefore no longer required routinely when modern multimodal imaging already establishes the phenotype.

Fluorescein Angiography Findings

FA may show:

• Dark choroid
• Hyperfluorescent window defects from RPE atrophy
• Fleck-related staining
• Areas of macular atrophy

It is most useful when:

• CNV is suspected
• The diagnosis remains uncertain

Full-Field ERG

The full-field ERG may be:

Normal in macula-limited disease

because most peripheral retinal function remains preserved.

However, some patients develop generalized retinal dysfunction.

ERG and Prognostic Subgroups

A useful functional classification includes:

Group 1

• Macular dysfunction only
• Normal full-field ERG

Group 2

• Macular disease plus generalized cone dysfunction

Group 3

• Generalized cone and rod dysfunction

Groups with generalized ERG abnormalities generally have:

More extensive disease and poorer prognosis.

Multifocal ERG

Multifocal ERG can demonstrate:

• Reduced central responses
• Regional macular dysfunction

It can be useful when:

• The fundus appearance is subtle
• Central dysfunction needs objective confirmation

but is not required in every patient.

Genetic Testing Is Now Important

An important modern correction is:

Genetic testing is now routinely useful and often recommended in suspected Stargardt disease.

Modern inherited retinal disease panels can identify pathogenic variants in:

• ABCA4
• Other macular dystrophy genes

This helps with:

• Confirming diagnosis
• Distinguishing phenocopies
• Genetic counseling
• Trial eligibility

Why ABCA4 Testing Can Be Complex

ABCA4 is highly polymorphic and has:

• Many pathogenic variants
• Hypomorphic alleles
• Deep intronic variants
• Complex genotype-phenotype relationships

Therefore results should ideally be interpreted with:

Inherited retinal disease genetic counseling.

Important Diagnostic Alternatives

Conditions that may resemble Stargardt disease include:

• Cone dystrophy
• Cone-rod dystrophy
• Pattern dystrophy
• PRPH2-associated macular dystrophy
• Best disease
• Central areolar choroidal dystrophy
• Hydroxychloroquine toxicity
• Bull’s-eye maculopathy from other causes

White-Dot and Flecked Retina Mimics

Conditions with retinal flecks include:

• Fundus albipunctatus
• Retinitis punctata albescens
• Bietti crystalline dystrophy
• Pattern dystrophy

The distribution and associated functional findings help differentiate them.

Distinguishing It From Fundus Albipunctatus

Stargardt Disease

• Central visual loss
• Macular atrophy
• Pisciform flecks
• ABCA4-related in classic disease

Fundus Albipunctatus

• Predominant night blindness
• Numerous white dots
• Often relatively preserved central acuity early
• Usually associated with RDH5

Distinguishing It From Cone or Cone-Rod Dystrophy

Cone-dominant disease often produces:

• Severe photophobia
• Marked color vision loss
• Generalized cone ERG abnormalities

Stargardt disease may have relatively preserved full-field ERG early.

Distinguishing It From Hydroxychloroquine Toxicity

Hydroxychloroquine toxicity may produce:

• Bull’s-eye maculopathy
• Parafoveal outer retinal loss

but history of drug exposure and characteristic OCT/field distribution help separate it from inherited Stargardt disease.

Is There a Curative Treatment?

At present:

There is no approved therapy proven to halt or reverse ABCA4-associated Stargardt disease.

Management is focused on:

• Visual rehabilitation
• Genetic counseling
• Monitoring
• Clinical trial consideration

Avoiding Excess Vitamin A

Because ABCA4 disease involves abnormal handling of vitamin A derivatives, patients are generally advised to:

Avoid high-dose vitamin A supplementation

unless there is a separate medically documented indication.

This does not mean avoiding normal dietary vitamin A.

Light Protection

Many clinicians recommend:

• Sunglasses
• Avoidance of unnecessary intense light exposure

because experimental data suggest that light may contribute to bisretinoid-mediated toxicity.

However:

There is no definitive evidence that routine sunglasses substantially alter the long-term disease course.

They remain reasonable for:

• Comfort
• Photophobia
• General retinal light protection

Low-Vision Rehabilitation

Low-vision services are extremely important once central vision becomes impaired.

Useful aids include:

• High-add reading lenses
• Electronic magnification
• Screen enlargement
• Text-to-speech software
• Contrast enhancement
• Portable video magnifiers

Educational and Occupational Support

Younger patients may benefit from:

• Preferential classroom seating
• Electronic textbooks
• Enlarged print
• Extra examination time
• Accessibility software

Early rehabilitation can maintain independence despite central visual loss.

Managing Choroidal Neovascularization

CNV is uncommon but can occur in areas of macular atrophy.

If CNV develops, treatment with:

Intravitreal anti-VEGF therapy

is appropriate.

Emerging Therapies

Research strategies include:

• Gene-based therapy
• RNA-based approaches
• Visual-cycle modulation
• Complement/inflammation modulation
• Cell-based therapy
• Pharmacologic reduction of toxic bisretinoid accumulation

These remain:

Investigational

and are not yet standard treatment.

Why ABCA4 Gene Therapy Is Challenging

ABCA4 is a relatively large gene, making delivery with conventional:

AAV vectors

technically difficult.

Strategies under investigation include:

• Dual-vector systems
• Alternative viral vectors
• Nonviral delivery
• RNA-based approaches

Monitoring Over Time

Follow-up is individualized but typically includes:

• Visual acuity
• OCT
• FAF
• Color vision or visual field testing when useful
• Low-vision needs

Annual review is reasonable for many stable patients, with closer follow-up when:

• Progression is rapid
• New symptoms arise
• CNV is suspected

What Patients Should Report Promptly

New:

• Sudden central blur
• Metamorphopsia
• New central distortion
• Rapid change in scotoma

should prompt evaluation for:

CNV or another superimposed macular complication.

Expected Disease Course

The natural history is highly variable.

Some patients develop rapid central vision loss in childhood, whereas others maintain useful central vision into adulthood.

In general:

Earlier onset tends to correlate with more severe and widespread retinal degeneration.

Visual Acuity Does Not Follow One Fixed Endpoint

Older teaching suggested that vision inevitably stabilizes around:

• 20/200
• 20/400

This is an oversimplification.

Final acuity varies widely according to:

• Age of onset
• Genotype
• Foveal involvement
• Presence of foveal sparing
• Extent of atrophy

Peripheral Vision

Peripheral visual function is often:

Well preserved in early STGD1

because disease initially concentrates in the macula.

Patients with advanced generalized ABCA4 disease may eventually develop:

• Peripheral retinal dysfunction
• Cone-rod dystrophy phenotype

Long-Term Complications

Potential consequences include:

• Progressive central vision loss
• Central scotoma
• Dyschromatopsia
• Photophobia
• RPE and photoreceptor atrophy
• Rare CNV
• Generalized cone-rod dysfunction in severe disease

High-Yield Takeaways

• Stargardt disease is the most common inherited juvenile macular dystrophy and is usually caused by biallelic ABCA4 variants.
• Classic STGD1 is autosomal recessive, so a strong multigenerational family history is often absent.
• ABCA4 dysfunction causes accumulation of toxic bisretinoids and lipofuscin within the RPE.
• The classic fundus findings are beaten-bronze macular change, yellow-white pisciform flecks, and progressive macular atrophy.
• Fundus flavimaculatus is an older descriptive term within the Stargardt spectrum rather than a clearly separate disease.
• Early disease can have a nearly normal fundus despite substantial visual symptoms.
• FAF and OCT are the key modern imaging modalities.
• FAF commonly shows hyperautofluorescent flecks and hypoautofluorescent RPE atrophy.
• OCT demonstrates ellipsoid-zone disruption, outer retinal loss, and progressive RPE atrophy.
• The classic dark choroid on fluorescein angiography is characteristic but not always present.
• Full-field ERG is often normal in macula-limited disease but may become abnormal when disease extends into generalized cone or cone-rod dysfunction.
• Contrary to older teaching, genetic testing is now an important part of diagnosis and counseling, usually through inherited retinal disease panels.
• Patients should generally avoid high-dose vitamin A supplements, although normal dietary vitamin A does not need to be eliminated.
• There is currently no approved disease-modifying treatment, but gene, RNA, pharmacologic, and cell-based therapies remain under investigation.
• Low-vision rehabilitation and educational support can substantially improve function and independence.
• Secondary CNV, although uncommon, should be treated with intravitreal anti-VEGF therapy.
• Visual prognosis is highly variable; there is no universal endpoint such as 20/200 or 20/400.
• Earlier-onset disease generally carries a worse prognosis, while later-onset disease may show foveal sparing and relatively preserved central vision for longer.

Ophthalmology – Solar Retinopathy

What the Injury Represents

Solar retinopathy is a phototoxic maculopathy caused by direct viewing of the sun or other intense light sources.

Damage is concentrated at the:

• Foveal photoreceptors
• Outer retina
• Retinal pigment epithelium (RPE)

The typical consequence is:

Bilateral central or paracentral visual disturbance after intense solar exposure.

It is also called:

• Solar maculopathy
• Eclipse retinopathy
• Photic retinopathy

Situations That Commonly Cause It

Typical exposures include:

• Looking directly at a solar eclipse
• Deliberate sun gazing
• Prolonged staring at the sun
• Religious or ritual sun viewing
• Psychiatric or drug-associated sun gazing

Similar photic injury can occur from:

• High-intensity welding arcs
• Powerful lasers
• Certain operating microscopes or ophthalmic light sources

although these are not strictly solar retinopathy.

Who Is at Greater Risk

Risk may be increased by:

• Direct unprotected solar viewing
• Repeated or prolonged exposure
• Clear optical media
• Aphakia
• Pharmacologic mydriasis
• Certain photosensitizing medications

Historically proposed risk factors include:

• Tetracycline-class drugs
• Psychedelic/hallucinogenic drug use
• Occupations involving prolonged sky observation

The most important risk factor remains:

Direct fixation on the sun.

Why Eclipses Are Particularly Dangerous

During a partial solar eclipse, ambient light becomes dimmer and the patient may:

• Experience less discomfort
• Maintain fixation longer
• Dilate the pupils somewhat

This can increase retinal exposure.

Importantly:

The sun is not intrinsically more damaging during an eclipse; the danger comes from prolonged unprotected viewing.

How the Retina Is Damaged

The principal mechanism is:

Photochemical injury

rather than a simple thermal burn.

Absorbed light generates:

• Reactive oxygen species
• Oxidative stress
• Photoreceptor outer-segment injury
• RPE damage

The outer retina is particularly vulnerable because the fovea receives highly concentrated light through the ocular optical system.

Important Modern Correction About Ultraviolet Light

Although older descriptions emphasized ultraviolet radiation, most ultraviolet light is absorbed by the:

• Cornea
• Crystalline lens

before reaching the retina.

Retinal phototoxicity is therefore primarily related to:

Visible and near-visible short-wavelength light reaching the macula.

Why the Fovea Is Preferentially Injured

The eye focuses incident light onto a very small retinal area.

The fovea is therefore exposed to a disproportionately high concentration of energy during:

Direct solar fixation.

This produces focal injury of:

• Photoreceptor outer segments
• Ellipsoid zone
• Interdigitation zone
• RPE

Typical Symptom Onset

Symptoms usually develop:

• Within hours
• Sometimes within 1–2 days

after exposure.

The patient may not experience pain during the exposure itself.

What Patients Notice

Common symptoms include:

• Blurred central vision
• Central scotoma
• Paracentral scotoma
• Metamorphopsia
• Dyschromatopsia
• Micropsia
• Reduced contrast sensitivity
• Photophobia

Disease is often:

Bilateral

but may be asymmetric depending on fixation behavior.

Typical Visual Acuity

Visual acuity may range from nearly normal to moderately reduced.

Some patients maintain relatively good Snellen acuity but still complain of:

• Persistent central blur
• Distortion
• Small scotoma

Therefore visual acuity alone may underestimate:

Functional macular damage.

Early Fundus Appearance

Early after injury, the macula may show:

• Small yellow-white foveal spot
• Subtle grayish discoloration
• Fine pigmentary change

The lesion may be extremely subtle.

In some patients:

The fundus initially appears almost normal.

Later Fundus Appearance

After several weeks, the acute yellow lesion may disappear.

Chronic findings range from:

• Normal-appearing macula
• Mild pigment mottling
• Focal RPE disturbance
• Small reddish foveal lesion
• Pseudohole-like appearance

These findings may persist despite improvement in acuity.

The Most Useful Imaging Test

Optical coherence tomography (OCT) is the key investigation.

It is more sensitive than ophthalmoscopy for detecting solar macular injury.

Acute OCT Findings

Early OCT may show:

• Focal hyperreflectivity involving the foveal outer retina
• Disruption of the ellipsoid zone
• Involvement of the outer nuclear layer
• RPE-level abnormalities

In more acute injury, hyperreflectivity may transiently extend into:

Inner retinal layers.

Chronic OCT Findings

Later OCT commonly shows:

• Persistent ellipsoid-zone disruption
• Interdigitation-zone loss
• Focal outer retinal thinning
• Small foveal hyporeflective defect
• RPE irregularity

A characteristic chronic finding is:

A focal outer-retinal defect centered at the fovea.

Why the Older “IS/OS Junction” Term Has Changed

Older OCT descriptions referred to damage at the:

Photoreceptor inner segment–outer segment junction

The modern term is:

Ellipsoid zone

which more accurately describes the corresponding OCT reflectivity band.

Fundus Autofluorescence

FAF may show:

• Subtle central hyperautofluorescence
• Hypoautofluorescent areas if RPE loss develops

Findings are variable, so FAF is mainly:

Supportive rather than diagnostic.

Fluorescein Angiography

FA is often:

Normal

especially early.

Later disease may show:

• Window defects
• Mild RPE transmission hyperfluorescence

Because FA often contributes little, it is generally less useful than:

OCT.

OCT Angiography

OCTA is usually not required.

Solar retinopathy primarily affects:

• Photoreceptors
• RPE

rather than retinal or choroidal vasculature.

OCTA may be considered only if another vascular macular disorder is suspected.

Visual Field Testing

Automated perimetry or microperimetry may demonstrate:

• Central scotoma
• Paracentral sensitivity loss

These defects can persist even after Snellen acuity improves.

Microperimetry

Microperimetry can be particularly helpful for:

• Quantifying central sensitivity loss
• Correlating functional deficit with OCT abnormalities

It is not necessary in routine uncomplicated cases.

Pathologic Changes

Histopathologic and experimental studies demonstrate injury primarily involving:

Photoreceptors

• Outer-segment swelling
• Disc disorganization
• Fragmentation
• Photoreceptor degeneration

RPE

• Pigmentary disruption
• Cellular injury
• Focal atrophy

The damage is concentrated in:

Foveal and parafoveal regions.

How the Diagnosis Is Made

Diagnosis usually rests on:

1. Compatible history of intense light exposure
2. Typical central visual symptoms
3. Characteristic outer retinal changes on OCT

No laboratory testing is required in a classic case.

Key History Questions

Ask about:

• Eclipse viewing
• Sun gazing
• Welding exposure
• Laser exposure
• Duration of exposure
• Protective eyewear
• Recreational drug use
• Psychiatric history where relevant
• Photosensitizing medications

The exposure history may initially be:

Unreported unless specifically asked.

Conditions That Can Look Similar

Important differential diagnoses include:

• Macular hole
• Early lamellar macular hole
• Macular telangiectasia type 2
• Acute macular neuroretinopathy
• Paracentral acute middle maculopathy
• Cone dystrophy
• Stargardt disease
• Central serous chorioretinopathy
• Age-related macular degeneration
• Laser-induced maculopathy

Distinguishing It From a Macular Hole

Solar retinopathy may produce a small central OCT defect that resembles a:

Lamellar or early macular hole

However, the history of photic exposure and predominant:

• Ellipsoid-zone disruption
• Outer retinal injury

favor solar retinopathy.

Distinguishing It From Laser Injury

Laser pointer or industrial laser injury can produce:

• Central scotoma
• Outer retinal disruption
• Macular pigmentary change

but the exposure history is different and hemorrhage may occur with high-energy laser injury.

Is There a Proven Treatment?

There is currently:

No proven treatment that reverses solar retinopathy.

Management is generally:

• Observation
• Reassurance
• Documentation with OCT
• Prevention of repeat exposure

Role of Corticosteroids

Systemic or local corticosteroids have occasionally been used historically, but:

There is no convincing evidence that steroids improve visual outcome in uncomplicated solar retinopathy.

Routine steroid treatment is therefore not recommended.

Why Observation Is Usually Appropriate

Most patients experience spontaneous improvement because:

• Acute outer retinal swelling resolves
• Surviving photoreceptors recover function
• Central sensitivity partially returns

Recovery is typically greatest during the:

First weeks to months.

Suggested Monitoring

Follow-up can include:

• Visual acuity
• Amsler grid symptoms
• OCT

An initial reassessment after several weeks is often sufficient in uncomplicated disease.

More frequent review is appropriate when:

• Diagnosis is uncertain
• Visual acuity worsens
• OCT findings are atypical

A rigid monthly schedule is not necessary for every patient.

Expected Visual Recovery

The prognosis is generally:

Favorable

Most patients recover useful central vision over:

• Weeks
• Several months

Final acuity may approach baseline even when OCT remains abnormal.

What Can Persist

Despite improvement in visual acuity, some patients continue to notice:

• Central scotoma
• Metamorphopsia
• Reduced contrast
• Dyschromatopsia
• Photophobia

These symptoms correlate with persistent outer retinal damage.

Features Linked to a Worse Outcome

Less complete recovery is more likely when there is:

• Severe initial visual loss
• Extensive ellipsoid-zone damage
• RPE atrophy
• Repeated solar exposure
• Large or dense central scotoma

Long-Term Structural Changes

Persistent abnormalities may include:

• Ellipsoid-zone loss
• Outer retinal thinning
• RPE mottling
• Small central atrophic defect

Severe permanent vision loss is uncommon after a single uncomplicated exposure.

Preventing Solar Retinopathy

The most important intervention is:

Never look directly at the sun without appropriate certified solar filters.

Ordinary sunglasses are:

Not adequate for direct solar viewing.

Safe Eclipse Viewing

For direct viewing of a partial solar eclipse, use:

Eclipse viewers or handheld solar filters that meet ISO 12312-2 requirements

and follow manufacturer safety instructions.

Safe alternatives include:

• Pinhole projection
• Other indirect projection techniques

What Should Never Be Used for Direct Solar Viewing

Do not rely on:

• Regular sunglasses
• Multiple stacked sunglasses
• Smoked glass
• Photographic film
• CDs/DVDs
• Homemade filters

These may reduce visible brightness without adequately blocking hazardous radiation.

Binoculars and Telescopes Require Special Care

Never look at the sun through:

• Binoculars
• Telescopes
• Camera lenses

unless an appropriate:

Solar filter is securely mounted over the front aperture of the optical device.

Concentrated sunlight can cause severe retinal injury almost immediately.

Possible Long-Term Problems

Complications are uncommon but may include:

• Persistent central scotoma
• Permanent metamorphopsia
• Dyschromatopsia
• Focal photoreceptor loss
• RPE atrophy
• Permanent reduction in central vision

The principal complication is:

Residual foveal photoreceptor damage.

High-Yield Takeaways

• Solar retinopathy is phototoxic injury of the foveal photoreceptors and RPE caused by direct viewing of the sun or another intense light source.
• The classic setting is unprotected eclipse viewing or deliberate sun gazing.
• Injury is primarily photochemical rather than thermal.
• The key retinal structures affected are the outer retina, ellipsoid zone, photoreceptor outer segments, and RPE.
• Symptoms include central blur, central/paracentral scotoma, metamorphopsia, dyschromatopsia, and reduced contrast sensitivity.
• Disease is typically bilateral but may be asymmetric.
• Early fundus examination may show a small yellow-white foveal spot, but the retina can look almost normal.
• OCT is the most useful diagnostic test and typically demonstrates focal outer-retinal and ellipsoid-zone disruption.
• The older OCT term “IS/OS junction” has largely been replaced by ellipsoid zone.
• Fluorescein angiography is frequently normal and is usually less useful than OCT.
• No laboratory investigation is required when the exposure history and OCT appearance are typical.
• There is no proven specific treatment; most cases are managed with observation and avoidance of further exposure.
• Routine corticosteroids are not supported by convincing evidence.
• Most patients experience substantial visual improvement over weeks to months, although a central scotoma or metamorphopsia may persist.
• Normal or near-normal Snellen acuity does not exclude persistent functional impairment.
• Ordinary sunglasses are not safe for direct solar viewing.
• Proper eclipse viewing requires ISO 12312-2-compliant solar viewers or a safe indirect projection method.
• The best treatment is prevention: direct solar fixation should always be avoided without an appropriate solar filter.